[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fr9u3kDji_0SD8xGlO2c4E4ClsCZbA8YsEkGhImlumwc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"University Hospital, Ghent",[4],677,false,144,20,182452,31,529,[14,17,20,22,25,28,30,33],{"name":15,"count":16},"Prostate Cancer",13,{"name":18,"count":19},"Epilepsy",12,{"name":21,"count":19},"Stroke",{"name":23,"count":24},"Psoriasis Vulgaris",9,{"name":26,"count":27},"Dental Implants",8,{"name":29,"count":27},"Nocturia",{"name":31,"count":32},"Breast Cancer",7,{"name":34,"count":32},"Healthy",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03569241","PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases","2023-04-30","androgen deprivation therapy",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04435288","Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","2025-05-31","week 24",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04188743","Decolonization of Gram-negative Multi-resistant Organisms (MDRO) with Donor Microbiota (FMT)","2025-12-30","Allogenic FMT",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05277766","Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer","2026-01","PIPAC with Nal-IRI",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06378229","Psilocybin for Hospitalized Patients with Treatment-resistant Depression","2026-03","Psilocybin",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05562518","GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.","2026-03-02","Estrogen",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT04553081","2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial","2026-06-30","Dual versus triple therapy in treatment of HIV-1 infection.",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07585487","Paracetamol and Cefazolin Pharmacokinetics in Normal Weight and Overweight Children","2027-01-30","Cefazolin",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06929702","Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children","2027-10-01","Beta-lactam antibiotic",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06234761","Immunological Mechanisms Underlying Mucosal IgE Responses","2027-12","Dupilumab",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,129,147,165,183,201,226,244,262,280,304,330,348,366,388,410,428,453,471,489,507,531,557,578,607,633,658,679,700,718,742,768,818,866,901,938,977,1002,1028,1053,1082,1100,1118,1136,1163,1181,1207,1225,1252,1270,1293,1319,1337,1363,1381,1407,1433,1451,1477,1503,1521,1546,1571,1596,1614,1639,1663,1687,1714,1738,1763,1789,1807,1830,1854,1872,1902,1920,1945,1963,1987,2005,2031,2060,2082,2107,2125,2154,2172,2197,2224,2242,2260,2285,2310,2334,2361,2379,2397,2421,2446,2464,2506,2530,2556,2583,2601,2619,2647,2665,2689,2715,2739,2764,2797,2824,2854,2878,2896,2925,2950,2968,2993,3016,3040,3066,3084,3102,3124,3148,3172,3197,3215,3240,3258,3283,3301,3324,3348,3374,3392,3417,3441,3463,3486,3504,3527,3552,3575,3598,3623,3646,3674,3692,3710,3735,3759,3783,3801,3819,3842,3867,3892,3927,3945,3963,3981,3999,4017,4035,4053,4071,4089,4107,4125,4149,4173,4199,4229,4252,4276,4301,4319,4354,4376,4398,4421,4439,4462,4487,4505,4538,4565,4583,4601,4619,4637,4665,4690,4708,4733,4751,4776,4808,4826,4844,4862,4880,4898,4916,4934,4958,4980,5004,5030,5053,5071,5099,5117,5144,5162,5180,5204,5222,5240,5264,5289],{"intervention":95,"totalTrials":96,"cells":97},"Elonva®",1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":127},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":122},"NCT06175832","PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study","RECRUITING",[91],"2027-12-31","2025-01-27",60,[118,119,120,121],"Ovarian Stimulation","Quality of Life","Preimplantation Genetic Testing","Fertility Preservation",[95,123,124,125,126],"Puregon®","Orgalutran®","Gonapeptyl®","Cerazette®",{"trials":128,"activeCount":100},[],{"intervention":123,"totalTrials":96,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":145},{"trials":132,"activeCount":100},[],{"trials":134,"activeCount":100},[],{"trials":136,"activeCount":100},[],{"trials":138,"activeCount":100},[],{"trials":140,"activeCount":96,"soonestReadout":114},[141],{"nctId":110,"briefTitle":111,"status":112,"phases":142,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":143,"interventions":144},[91],[118,119,120,121],[95,123,124,125,126],{"trials":146,"activeCount":100},[],{"intervention":124,"totalTrials":96,"cells":148},{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":157,"NA":163},{"trials":150,"activeCount":100},[],{"trials":152,"activeCount":100},[],{"trials":154,"activeCount":100},[],{"trials":156,"activeCount":100},[],{"trials":158,"activeCount":96,"soonestReadout":114},[159],{"nctId":110,"briefTitle":111,"status":112,"phases":160,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":161,"interventions":162},[91],[118,119,120,121],[95,123,124,125,126],{"trials":164,"activeCount":100},[],{"intervention":125,"totalTrials":96,"cells":166},{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":181},{"trials":168,"activeCount":100},[],{"trials":170,"activeCount":100},[],{"trials":172,"activeCount":100},[],{"trials":174,"activeCount":100},[],{"trials":176,"activeCount":96,"soonestReadout":114},[177],{"nctId":110,"briefTitle":111,"status":112,"phases":178,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":179,"interventions":180},[91],[118,119,120,121],[95,123,124,125,126],{"trials":182,"activeCount":100},[],{"intervention":126,"totalTrials":96,"cells":184},{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":199},{"trials":186,"activeCount":100},[],{"trials":188,"activeCount":100},[],{"trials":190,"activeCount":100},[],{"trials":192,"activeCount":100},[],{"trials":194,"activeCount":96,"soonestReadout":114},[195],{"nctId":110,"briefTitle":111,"status":112,"phases":196,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":197,"interventions":198},[91],[118,119,120,121],[95,123,124,125,126],{"trials":200,"activeCount":100},[],{"intervention":65,"totalTrials":96,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":224},{"trials":204,"activeCount":100},[],{"trials":206,"activeCount":100},[],{"trials":208,"activeCount":100},[],{"trials":210,"activeCount":100},[],{"trials":212,"activeCount":96,"soonestReadout":64},[213],{"nctId":62,"briefTitle":63,"status":214,"phases":215,"primaryCompletion":64,"completion":114,"start":216,"enrollment":217,"conditions":218,"interventions":220},"ACTIVE_NOT_RECRUITING",[91],"2022-03-21",160,[219,31],"Vulvovaginal Atrophy",[65,221,222,223],"dehydroepiandrosterone","Estrogen + probiotics","Moisturizer",{"trials":225,"activeCount":100},[],{"intervention":221,"totalTrials":96,"cells":227},{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":242},{"trials":229,"activeCount":100},[],{"trials":231,"activeCount":100},[],{"trials":233,"activeCount":100},[],{"trials":235,"activeCount":100},[],{"trials":237,"activeCount":96,"soonestReadout":64},[238],{"nctId":62,"briefTitle":63,"status":214,"phases":239,"primaryCompletion":64,"completion":114,"start":216,"enrollment":217,"conditions":240,"interventions":241},[91],[219,31],[65,221,222,223],{"trials":243,"activeCount":100},[],{"intervention":222,"totalTrials":96,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":260},{"trials":247,"activeCount":100},[],{"trials":249,"activeCount":100},[],{"trials":251,"activeCount":100},[],{"trials":253,"activeCount":100},[],{"trials":255,"activeCount":96,"soonestReadout":64},[256],{"nctId":62,"briefTitle":63,"status":214,"phases":257,"primaryCompletion":64,"completion":114,"start":216,"enrollment":217,"conditions":258,"interventions":259},[91],[219,31],[65,221,222,223],{"trials":261,"activeCount":100},[],{"intervention":223,"totalTrials":96,"cells":263},{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":270,"PHASE4":272,"NA":278},{"trials":265,"activeCount":100},[],{"trials":267,"activeCount":100},[],{"trials":269,"activeCount":100},[],{"trials":271,"activeCount":100},[],{"trials":273,"activeCount":96,"soonestReadout":64},[274],{"nctId":62,"briefTitle":63,"status":214,"phases":275,"primaryCompletion":64,"completion":114,"start":216,"enrollment":217,"conditions":276,"interventions":277},[91],[219,31],[65,221,222,223],{"trials":279,"activeCount":100},[],{"intervention":80,"totalTrials":96,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":302},{"trials":283,"activeCount":100},[],{"trials":285,"activeCount":100},[],{"trials":287,"activeCount":100},[],{"trials":289,"activeCount":100},[],{"trials":291,"activeCount":96,"soonestReadout":79},[292],{"nctId":77,"briefTitle":78,"status":293,"phases":294,"primaryCompletion":79,"completion":79,"start":295,"enrollment":296,"conditions":297,"interventions":301},"NOT_YET_RECRUITING",[91],"2025-04-22",58,[298,299,300],"Amoxicillin-clavulanate","Piperacillin-tazobactam","Meropenem",[80],{"trials":303,"activeCount":100},[],{"intervention":305,"totalTrials":96,"cells":306},"Proactive TDM-based dosing of secukinumab",{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":315,"NA":328},{"trials":308,"activeCount":100},[],{"trials":310,"activeCount":100},[],{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":100},[],{"trials":316,"activeCount":96,"soonestReadout":321},[317],{"nctId":318,"briefTitle":319,"status":112,"phases":320,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":325},"NCT06398106","Proactive TDM Versus Standard Use of Biologics in Psoriasis",[91],"2028-03-01","2024-12-20",210,[23],[305,326,327],"Proactive TDM-based dosing of ixekizumab","Proactive TDM-based dosing of guselkumab",{"trials":329,"activeCount":100},[],{"intervention":326,"totalTrials":96,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":340,"NA":346},{"trials":333,"activeCount":100},[],{"trials":335,"activeCount":100},[],{"trials":337,"activeCount":100},[],{"trials":339,"activeCount":100},[],{"trials":341,"activeCount":96,"soonestReadout":321},[342],{"nctId":318,"briefTitle":319,"status":112,"phases":343,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":344,"interventions":345},[91],[23],[305,326,327],{"trials":347,"activeCount":100},[],{"intervention":327,"totalTrials":96,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":358,"NA":364},{"trials":351,"activeCount":100},[],{"trials":353,"activeCount":100},[],{"trials":355,"activeCount":100},[],{"trials":357,"activeCount":100},[],{"trials":359,"activeCount":96,"soonestReadout":321},[360],{"nctId":318,"briefTitle":319,"status":112,"phases":361,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":362,"interventions":363},[91],[23],[305,326,327],{"trials":365,"activeCount":100},[],{"intervention":70,"totalTrials":96,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":376,"NA":386},{"trials":369,"activeCount":100},[],{"trials":371,"activeCount":100},[],{"trials":373,"activeCount":100},[],{"trials":375,"activeCount":100},[],{"trials":377,"activeCount":96,"soonestReadout":69},[378],{"nctId":67,"briefTitle":68,"status":112,"phases":379,"primaryCompletion":69,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":385},[91],"2027-04-30","2020-05-26",134,[384],"HIV-1-infection",[70],{"trials":387,"activeCount":100},[],{"intervention":50,"totalTrials":96,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":406,"NA":408},{"trials":391,"activeCount":100},[],{"trials":393,"activeCount":100},[],{"trials":395,"activeCount":100},[],{"trials":397,"activeCount":96,"soonestReadout":49},[398],{"nctId":47,"briefTitle":48,"status":112,"phases":399,"primaryCompletion":49,"completion":49,"start":400,"enrollment":401,"conditions":402,"interventions":404},[89,90],"2019-12-18",150,[403],"Resistance Bacterial",[50,405],"Autologous FMT",{"trials":407,"activeCount":100},[],{"trials":409,"activeCount":100},[],{"intervention":405,"totalTrials":96,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":424,"NA":426},{"trials":413,"activeCount":100},[],{"trials":415,"activeCount":100},[],{"trials":417,"activeCount":100},[],{"trials":419,"activeCount":96,"soonestReadout":49},[420],{"nctId":47,"briefTitle":48,"status":112,"phases":421,"primaryCompletion":49,"completion":49,"start":400,"enrollment":401,"conditions":422,"interventions":423},[89,90],[403],[50,405],{"trials":425,"activeCount":100},[],{"trials":427,"activeCount":100},[],{"intervention":45,"totalTrials":96,"cells":429},{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":449,"NA":451},{"trials":431,"activeCount":100},[],{"trials":433,"activeCount":100},[],{"trials":435,"activeCount":100},[],{"trials":437,"activeCount":96,"soonestReadout":44},[438],{"nctId":42,"briefTitle":43,"status":214,"phases":439,"primaryCompletion":44,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":445},[90],"2028-12-31","2020-08-24",90,[444],"Peripheral Spondyloarthritis",[45,446,447,448],"week 36","Week 48","Week 60",{"trials":450,"activeCount":100},[],{"trials":452,"activeCount":100},[],{"intervention":446,"totalTrials":96,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":467,"NA":469},{"trials":456,"activeCount":100},[],{"trials":458,"activeCount":100},[],{"trials":460,"activeCount":100},[],{"trials":462,"activeCount":96,"soonestReadout":44},[463],{"nctId":42,"briefTitle":43,"status":214,"phases":464,"primaryCompletion":44,"completion":440,"start":441,"enrollment":442,"conditions":465,"interventions":466},[90],[444],[45,446,447,448],{"trials":468,"activeCount":100},[],{"trials":470,"activeCount":100},[],{"intervention":447,"totalTrials":96,"cells":472},{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":485,"NA":487},{"trials":474,"activeCount":100},[],{"trials":476,"activeCount":100},[],{"trials":478,"activeCount":100},[],{"trials":480,"activeCount":96,"soonestReadout":44},[481],{"nctId":42,"briefTitle":43,"status":214,"phases":482,"primaryCompletion":44,"completion":440,"start":441,"enrollment":442,"conditions":483,"interventions":484},[90],[444],[45,446,447,448],{"trials":486,"activeCount":100},[],{"trials":488,"activeCount":100},[],{"intervention":448,"totalTrials":96,"cells":490},{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":503,"NA":505},{"trials":492,"activeCount":100},[],{"trials":494,"activeCount":100},[],{"trials":496,"activeCount":100},[],{"trials":498,"activeCount":96,"soonestReadout":44},[499],{"nctId":42,"briefTitle":43,"status":214,"phases":500,"primaryCompletion":44,"completion":440,"start":441,"enrollment":442,"conditions":501,"interventions":502},[90],[444],[45,446,447,448],{"trials":504,"activeCount":100},[],{"trials":506,"activeCount":100},[],{"intervention":40,"totalTrials":96,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":525,"PHASE4":527,"NA":529},{"trials":510,"activeCount":100},[],{"trials":512,"activeCount":100},[],{"trials":514,"activeCount":96,"soonestReadout":39},[515],{"nctId":37,"briefTitle":38,"status":214,"phases":516,"primaryCompletion":39,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":524},[89],"2026-12-31","2018-04-27",196,[15,521,522,523],"Prostate Cancer Metastatic","Metastatic Cancer","Oligometastatic Cancer",[40],{"trials":526,"activeCount":100},[],{"trials":528,"activeCount":100},[],{"trials":530,"activeCount":100},[],{"intervention":532,"totalTrials":96,"cells":533},"Immunotherapy",{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":551,"PHASE4":553,"NA":555},{"trials":535,"activeCount":100},[],{"trials":537,"activeCount":100},[],{"trials":539,"activeCount":96,"soonestReadout":544},[540],{"nctId":541,"briefTitle":542,"status":112,"phases":543,"primaryCompletion":544,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":550},"NCT04724928","Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer",[89],"2029-12-31","2030-05","2021-04-29",156,[549],"Muscle-Invasive Bladder Carcinoma",[532],{"trials":552,"activeCount":100},[],{"trials":554,"activeCount":100},[],{"trials":556,"activeCount":100},[],{"intervention":60,"totalTrials":96,"cells":558},{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":560,"activeCount":100},[],{"trials":562,"activeCount":100},[],{"trials":564,"activeCount":96,"soonestReadout":59},[565],{"nctId":57,"briefTitle":58,"status":112,"phases":566,"primaryCompletion":59,"completion":517,"start":567,"enrollment":568,"conditions":569,"interventions":571},[89],"2024-05-21",100,[570],"Treatment Resistant Depression",[60],{"trials":573,"activeCount":100},[],{"trials":575,"activeCount":100},[],{"trials":577,"activeCount":100},[],{"intervention":55,"totalTrials":96,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":599,"PHASE3":601,"PHASE4":603,"NA":605},{"trials":581,"activeCount":100},[],{"trials":583,"activeCount":96,"soonestReadout":54},[584],{"nctId":52,"briefTitle":53,"status":112,"phases":585,"primaryCompletion":54,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":598},[88],"2027-04","2022-11-21",45,[590,591,592,593,594,595,596,597],"Peritoneal Carcinomatosis","Peritoneal Metastases","Colorectal Cancer","Small Bowel Cancer","Appendix Cancer","Gastric Cancer","Pancreatic Cancer","Bile Duct Cancer",[55],{"trials":600,"activeCount":100},[],{"trials":602,"activeCount":100},[],{"trials":604,"activeCount":100},[],{"trials":606,"activeCount":100},[],{"intervention":608,"totalTrials":96,"cells":609},"Hormonal substitution therapy per SOC",{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":614,"PHASE3":616,"PHASE4":618,"NA":620},{"trials":611,"activeCount":100},[],{"trials":613,"activeCount":100},[],{"trials":615,"activeCount":100},[],{"trials":617,"activeCount":100},[],{"trials":619,"activeCount":100},[],{"trials":621,"activeCount":96,"soonestReadout":114},[622],{"nctId":623,"briefTitle":624,"status":112,"phases":625,"primaryCompletion":114,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":632},"NCT05831709","The Influence of Hormone Replacement Therapy and Supervised Exercise Training on Body Composition, Cardiovascular Risk and Insulin Sensitivity in Postmenopausal Women",[92],"2028-12","2023-05-12",390,[630,631],"Postmenopause","Menopausal Complaints",[608],{"intervention":634,"totalTrials":96,"cells":635},"Mepolizumab",{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":642,"PHASE4":644,"NA":646},{"trials":637,"activeCount":100},[],{"trials":639,"activeCount":100},[],{"trials":641,"activeCount":100},[],{"trials":643,"activeCount":100},[],{"trials":645,"activeCount":100},[],{"trials":647,"activeCount":96,"soonestReadout":652},[648],{"nctId":649,"briefTitle":650,"status":112,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":657},"NCT05938972","Real Life Study of Biologicals in Patients With Severe CRSwNP",[],"2030-12-31","2022-03-01",180,[656],"Chronic Rhinosinusitis With Nasal Polyps",[634],{"intervention":85,"totalTrials":96,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":670},{"trials":661,"activeCount":100},[],{"trials":663,"activeCount":100},[],{"trials":665,"activeCount":100},[],{"trials":667,"activeCount":100},[],{"trials":669,"activeCount":100},[],{"trials":671,"activeCount":96,"soonestReadout":84},[672],{"nctId":82,"briefTitle":83,"status":112,"phases":673,"primaryCompletion":84,"completion":626,"start":674,"enrollment":675,"conditions":676,"interventions":678},[],"2024-01-02",50,[677],"Pathophysiology",[85],{"intervention":75,"totalTrials":96,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":689,"NA":691},{"trials":682,"activeCount":100},[],{"trials":684,"activeCount":100},[],{"trials":686,"activeCount":100},[],{"trials":688,"activeCount":100},[],{"trials":690,"activeCount":100},[],{"trials":692,"activeCount":96,"soonestReadout":74},[693],{"nctId":72,"briefTitle":73,"status":112,"phases":694,"primaryCompletion":74,"completion":74,"start":695,"enrollment":696,"conditions":697,"interventions":699},[],"2023-12-22",120,[698,75],"Paracetamol",[75,698],{"intervention":698,"totalTrials":96,"cells":701},{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":703,"activeCount":100},[],{"trials":705,"activeCount":100},[],{"trials":707,"activeCount":100},[],{"trials":709,"activeCount":100},[],{"trials":711,"activeCount":100},[],{"trials":713,"activeCount":96,"soonestReadout":74},[714],{"nctId":72,"briefTitle":73,"status":112,"phases":715,"primaryCompletion":74,"completion":74,"start":695,"enrollment":696,"conditions":716,"interventions":717},[],[698,75],[75,698],{"intervention":719,"totalTrials":96,"cells":720},"blood sampling",{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":722,"activeCount":100},[],{"trials":724,"activeCount":100},[],{"trials":726,"activeCount":100},[],{"trials":728,"activeCount":100},[],{"trials":730,"activeCount":100},[],{"trials":732,"activeCount":96,"soonestReadout":652},[733],{"nctId":734,"briefTitle":735,"status":112,"phases":736,"primaryCompletion":652,"completion":652,"start":737,"enrollment":738,"conditions":739,"interventions":741},"NCT01072825","A European Network for the Investigation of Gender Incongruence",[],"2010-02-15",125,[740],"Physical and Psychological Evaluation of Hormonal Therapy in Transsexual Persons",[719],{"intervention":743,"totalTrials":96,"cells":744},"Early combination anti-retroviral treatment",{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":751,"PHASE4":753,"NA":755},{"trials":746,"activeCount":100},[],{"trials":748,"activeCount":100},[],{"trials":750,"activeCount":100},[],{"trials":752,"activeCount":100},[],{"trials":754,"activeCount":100},[],{"trials":756,"activeCount":96,"soonestReadout":761},[757],{"nctId":758,"briefTitle":759,"status":112,"phases":760,"primaryCompletion":761,"completion":761,"start":762,"enrollment":763,"conditions":764,"interventions":767},"NCT03449706","Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection",[],"2028-01-01","2017-09-01",70,[765,766],"HIV","Seroconversion, HIV",[743],{"intervention":769,"totalTrials":770,"cells":771},"Desmopressin",3,{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":778,"PHASE4":780,"NA":816},{"trials":773,"activeCount":100},[],{"trials":775,"activeCount":100},[],{"trials":777,"activeCount":100},[],{"trials":779,"activeCount":100},[],{"trials":781,"activeCount":100},[782,793,803],{"nctId":783,"briefTitle":784,"status":785,"phases":786,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":791,"interventions":792},"NCT01439997","Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study","COMPLETED",[91],"2013-02-01","2015-02-01","2012-03-26",5,[29],[769],{"nctId":794,"briefTitle":795,"status":785,"phases":796,"primaryCompletion":797,"completion":798,"start":799,"enrollment":675,"conditions":800,"interventions":802},"NCT01435083","Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic\u002FDynamic Study",[91],"2013-06","2013-07","2011-11",[801],"Nocturnal Polyuria",[769],{"nctId":804,"briefTitle":805,"status":785,"phases":806,"primaryCompletion":807,"completion":807,"start":808,"enrollment":809,"conditions":810,"interventions":813},"NCT01036841","Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation",[91],"2010-04","2009-12",24,[811,812],"Enuresis","Polyuria",[814,815],"desmopressin","desmopressin MELT formulation",{"trials":817,"activeCount":100},[],{"intervention":819,"totalTrials":770,"cells":820},"Dexmedetomidine",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":851,"NA":864},{"trials":822,"activeCount":100},[],{"trials":824,"activeCount":100},[],{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[829,840],{"nctId":830,"briefTitle":831,"status":832,"phases":833,"primaryCompletion":834,"completion":835,"start":808,"enrollment":96,"conditions":836,"interventions":838},"NCT01076816","Dexmedetomidine Pharmacokinetics-pharmacodynamics in Mechanically Ventilated Children With Single-organ Respiratory Failure","TERMINATED",[90],"2011-02","2011-05",[837],"Respiratory Failure",[839],"dexmedetomidine",{"nctId":841,"briefTitle":842,"status":785,"phases":843,"primaryCompletion":844,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":850},"NCT01266252","Dexmedetomidine in Mechanically Ventilated Neonates With Single-Organ Respiratory Failure.",[90],"2017-04-20","2018-04-10","2011-07-28",35,[849],"Mechanically-ventilated Neonates With Single-organ Respiratory Failure",[819],{"trials":852,"activeCount":100},[853],{"nctId":854,"briefTitle":855,"status":785,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":568,"conditions":860,"interventions":863},"NCT04987372","Multimodal Versus Opioid aNalgesia in carDiAc Surgery",[91],"2021-12-01","2021-12-03","2019-01-21",[861,862],"Postoperative Pain","Postoperative Delirium",[819],{"trials":865,"activeCount":100},[],{"intervention":867,"totalTrials":868,"cells":869},"Vancomycin",2,{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":876,"PHASE4":878,"NA":899},{"trials":871,"activeCount":100},[],{"trials":873,"activeCount":100},[],{"trials":875,"activeCount":100},[],{"trials":877,"activeCount":100},[],{"trials":879,"activeCount":100},[880,889],{"nctId":881,"briefTitle":882,"status":785,"phases":883,"primaryCompletion":884,"completion":884,"start":885,"enrollment":886,"conditions":887,"interventions":888},"NCT05535075","Model-informed Precision Dosing of Vancomycin in Adults",[91],"2023-11-17","2021-11-12",155,[867],[867],{"nctId":890,"briefTitle":891,"status":785,"phases":892,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":898},"NCT04666948","Precision Dosing of Vancomycin in Critically Ill Children",[91],"2023-12-14","2024-10-30","2020-12-28",314,[867],[867],{"trials":900,"activeCount":100},[],{"intervention":902,"totalTrials":868,"cells":903},"Metformin",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":936},{"trials":905,"activeCount":100},[],{"trials":907,"activeCount":100},[],{"trials":909,"activeCount":100},[],{"trials":911,"activeCount":100},[],{"trials":913,"activeCount":100},[914,924],{"nctId":915,"briefTitle":916,"status":785,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":921,"interventions":923},"NCT00134303","Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity",[91],"2006-03-31","2005-06",65,[922],"Obesity",[902],{"nctId":925,"briefTitle":926,"status":785,"phases":927,"completion":928,"start":929,"enrollment":930,"conditions":931,"interventions":934},"NCT00134290","The Effects of Calorie Restriction With or Without Metformin on Weight and Insulin Resistance",[91],"2004-05","2002-01",48,[932,933],"Body Weight","Insulin Resistance",[935],"metformin",{"trials":937,"activeCount":100},[],{"intervention":939,"totalTrials":868,"cells":940},"Phenylephrine",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":947,"PHASE4":949,"NA":975},{"trials":942,"activeCount":100},[],{"trials":944,"activeCount":100},[],{"trials":946,"activeCount":100},[],{"trials":948,"activeCount":100},[],{"trials":950,"activeCount":100},[951,963],{"nctId":952,"briefTitle":953,"status":785,"phases":954,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":959,"interventions":961},"NCT03767296","Influence of a Bolus Administration of Ephedrine and Phenylephrine on the Spinal Oxygen Saturation, Measured With NIRS.",[91],"2017-09-09","2018-12-04","2017-02-06",33,[960],"Influence of Vasoactive Medication on Spinal Oxygenation",[962,939],"Ephedrine Hydrochloride 3 MG\u002FML",{"nctId":964,"briefTitle":965,"status":785,"phases":966,"primaryCompletion":967,"completion":968,"start":969,"enrollment":970,"conditions":971,"interventions":973},"NCT03846765","Influence of Continuous Administration of Phenylephrine Versus Dobutamine on Spinal Oxygen Saturation, Measured With Near-infrared Spectroscopy (NIRS).",[91],"2021-05-22","2022-11-10","2019-07-04",36,[972],"Nfuence of Vasoactive Medication on Spinal Oxygenation",[939,974],"Dobutamine",{"trials":976,"activeCount":100},[],{"intervention":978,"totalTrials":96,"cells":979},"Desmopressin lyophilisate",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":1000},{"trials":981,"activeCount":100},[],{"trials":983,"activeCount":100},[],{"trials":985,"activeCount":100},[],{"trials":987,"activeCount":100},[],{"trials":989,"activeCount":100},[990],{"nctId":991,"briefTitle":992,"status":785,"phases":993,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":997,"interventions":999},"NCT01645475","Desmopressin Melt: Impact on Sleep and Daytime Functioning",[91],"2012-08","2011-04",30,[998],"Monosymptomatic Nocturnal Enuresis",[978],{"trials":1001,"activeCount":100},[],{"intervention":1003,"totalTrials":96,"cells":1004},"Ovitrelle",{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1009,"PHASE3":1011,"PHASE4":1013,"NA":1026},{"trials":1006,"activeCount":100},[],{"trials":1008,"activeCount":100},[],{"trials":1010,"activeCount":100},[],{"trials":1012,"activeCount":100},[],{"trials":1014,"activeCount":100},[1015],{"nctId":1016,"briefTitle":1017,"status":785,"phases":1018,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":958,"conditions":1021,"interventions":1025},"NCT03495609","Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers",[91],"2018-12-18","2016-02-17",[1022,1023,1024],"hCG","BRCA1 Mutation","BRCA2 Mutation",[1003],{"trials":1027,"activeCount":100},[],{"intervention":1029,"totalTrials":96,"cells":1030},"Sodium oxybate",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1037,"PHASE4":1039,"NA":1051},{"trials":1032,"activeCount":100},[],{"trials":1034,"activeCount":100},[],{"trials":1036,"activeCount":100},[],{"trials":1038,"activeCount":100},[],{"trials":1040,"activeCount":100},[1041],{"nctId":1042,"briefTitle":1043,"status":1044,"phases":1045,"primaryCompletion":1046,"completion":1047,"start":797,"enrollment":100,"conditions":1048,"interventions":1050},"NCT01584934","Sodium Oxybate in Patients With Chronic Fatigue Syndrome.","WITHDRAWN",[91],"2015-06","2015-12",[1049],"Chronic Fatigue Syndrome",[1029],{"trials":1052,"activeCount":100},[],{"intervention":1054,"totalTrials":96,"cells":1055},"topical tacrolimus treatment",{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1062,"PHASE4":1064,"NA":1080},{"trials":1057,"activeCount":100},[],{"trials":1059,"activeCount":100},[],{"trials":1061,"activeCount":100},[],{"trials":1063,"activeCount":100},[],{"trials":1065,"activeCount":100},[1066],{"nctId":1067,"briefTitle":1068,"status":785,"phases":1069,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1074,"interventions":1076},"NCT01082393","Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)",[91],"2015-09-15","2015-12-01","2010-02-16",14,[1075],"Vitiligo",[1054,1077,1078,1079],"topical pimecrolimus treatment","local mometasone furoate treatment","cold cream",{"trials":1081,"activeCount":100},[],{"intervention":1077,"totalTrials":96,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1092,"NA":1098},{"trials":1085,"activeCount":100},[],{"trials":1087,"activeCount":100},[],{"trials":1089,"activeCount":100},[],{"trials":1091,"activeCount":100},[],{"trials":1093,"activeCount":100},[1094],{"nctId":1067,"briefTitle":1068,"status":785,"phases":1095,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1096,"interventions":1097},[91],[1075],[1054,1077,1078,1079],{"trials":1099,"activeCount":100},[],{"intervention":1078,"totalTrials":96,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1110,"NA":1116},{"trials":1103,"activeCount":100},[],{"trials":1105,"activeCount":100},[],{"trials":1107,"activeCount":100},[],{"trials":1109,"activeCount":100},[],{"trials":1111,"activeCount":100},[1112],{"nctId":1067,"briefTitle":1068,"status":785,"phases":1113,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1114,"interventions":1115},[91],[1075],[1054,1077,1078,1079],{"trials":1117,"activeCount":100},[],{"intervention":1079,"totalTrials":96,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1134},{"trials":1121,"activeCount":100},[],{"trials":1123,"activeCount":100},[],{"trials":1125,"activeCount":100},[],{"trials":1127,"activeCount":100},[],{"trials":1129,"activeCount":100},[1130],{"nctId":1067,"briefTitle":1068,"status":785,"phases":1131,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1132,"interventions":1133},[91],[1075],[1054,1077,1078,1079],{"trials":1135,"activeCount":100},[],{"intervention":1137,"totalTrials":96,"cells":1138},"Acetylcysteine",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1147,"NA":1161},{"trials":1140,"activeCount":100},[],{"trials":1142,"activeCount":100},[],{"trials":1144,"activeCount":100},[],{"trials":1146,"activeCount":100},[],{"trials":1148,"activeCount":100},[1149],{"nctId":1150,"briefTitle":1151,"status":832,"phases":1152,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":1157,"interventions":1159},"NCT00996424","The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function",[91],"2010-09","2010-12","2010-01",19,[1158],"Cystic Fibrosis",[1137,1160],"normal saline",{"trials":1162,"activeCount":100},[],{"intervention":1160,"totalTrials":96,"cells":1164},{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1171,"PHASE4":1173,"NA":1179},{"trials":1166,"activeCount":100},[],{"trials":1168,"activeCount":100},[],{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[],{"trials":1174,"activeCount":100},[1175],{"nctId":1150,"briefTitle":1151,"status":832,"phases":1176,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":1177,"interventions":1178},[91],[1158],[1137,1160],{"trials":1180,"activeCount":100},[],{"intervention":1182,"totalTrials":96,"cells":1183},"piperacillin continuous",{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1190,"PHASE4":1192,"NA":1205},{"trials":1185,"activeCount":100},[],{"trials":1187,"activeCount":100},[],{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"trials":1193,"activeCount":100},[1194],{"nctId":1195,"briefTitle":1196,"status":785,"phases":1197,"primaryCompletion":1198,"completion":1199,"start":1200,"enrollment":1073,"conditions":1201,"interventions":1203},"NCT01198925","Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion",[91],"2012-11-16","2018-05-03","2010-09-23",[1202],"Infectious Disease",[1182,1204],"piperacillin extended",{"trials":1206,"activeCount":100},[],{"intervention":1204,"totalTrials":96,"cells":1208},{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1215,"PHASE4":1217,"NA":1223},{"trials":1210,"activeCount":100},[],{"trials":1212,"activeCount":100},[],{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"trials":1218,"activeCount":100},[1219],{"nctId":1195,"briefTitle":1196,"status":785,"phases":1220,"primaryCompletion":1198,"completion":1199,"start":1200,"enrollment":1073,"conditions":1221,"interventions":1222},[91],[1202],[1182,1204],{"trials":1224,"activeCount":100},[],{"intervention":1226,"totalTrials":96,"cells":1227},"Moviprep®",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1236,"NA":1250},{"trials":1229,"activeCount":100},[],{"trials":1231,"activeCount":100},[],{"trials":1233,"activeCount":100},[],{"trials":1235,"activeCount":100},[],{"trials":1237,"activeCount":100},[1238],{"nctId":1239,"briefTitle":1240,"status":785,"phases":1241,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":1246,"interventions":1248},"NCT00618930","Moviprep® Versus Fleet Phospho-Soda® (Golden Standard): A Study That Compared Two Laxatives on Patients Undergoing Colo-Rectal Cleansing Prior to an Abdominal Operation",[91],"2008-12","2009-01","2008-02",40,[1247],"Colorectal Cleansing Prior Operation",[1226,1249],"Fleet",{"trials":1251,"activeCount":100},[],{"intervention":1249,"totalTrials":96,"cells":1253},{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1258,"PHASE3":1260,"PHASE4":1262,"NA":1268},{"trials":1255,"activeCount":100},[],{"trials":1257,"activeCount":100},[],{"trials":1259,"activeCount":100},[],{"trials":1261,"activeCount":100},[],{"trials":1263,"activeCount":100},[1264],{"nctId":1239,"briefTitle":1240,"status":785,"phases":1265,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":1266,"interventions":1267},[91],[1247],[1226,1249],{"trials":1269,"activeCount":100},[],{"intervention":1271,"totalTrials":96,"cells":1272},"Dose reduction",{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1281,"NA":1291},{"trials":1274,"activeCount":100},[],{"trials":1276,"activeCount":100},[],{"trials":1278,"activeCount":100},[],{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[1283],{"nctId":1284,"briefTitle":1285,"status":832,"phases":1286,"primaryCompletion":1287,"completion":1287,"start":1288,"enrollment":1156,"conditions":1289,"interventions":1290},"NCT04028713","Dose Tapering Study of Adalimumab in Psoriasis",[91],"2022-03-22","2021-02-16",[23],[1271],{"trials":1292,"activeCount":100},[],{"intervention":1294,"totalTrials":96,"cells":1295},"Tramadol per os",{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1304,"NA":1317},{"trials":1297,"activeCount":100},[],{"trials":1299,"activeCount":100},[],{"trials":1301,"activeCount":100},[],{"trials":1303,"activeCount":100},[],{"trials":1305,"activeCount":100},[1306],{"nctId":1307,"briefTitle":1308,"status":785,"phases":1309,"primaryCompletion":1310,"completion":1310,"start":1311,"enrollment":1312,"conditions":1313,"interventions":1315},"NCT00735748","Comparison of Tramadol Orally Versus an Optimized Dose of Intravenous Tramadol for Postoperative Pain Relief in Ambulatory Surgery",[91],"2009-06-19","2008-03-01",195,[1314],"Pain",[1294,1316],"Tramadol IV",{"trials":1318,"activeCount":100},[],{"intervention":1316,"totalTrials":96,"cells":1320},{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1325,"PHASE3":1327,"PHASE4":1329,"NA":1335},{"trials":1322,"activeCount":100},[],{"trials":1324,"activeCount":100},[],{"trials":1326,"activeCount":100},[],{"trials":1328,"activeCount":100},[],{"trials":1330,"activeCount":100},[1331],{"nctId":1307,"briefTitle":1308,"status":785,"phases":1332,"primaryCompletion":1310,"completion":1310,"start":1311,"enrollment":1312,"conditions":1333,"interventions":1334},[91],[1314],[1294,1316],{"trials":1336,"activeCount":100},[],{"intervention":1338,"totalTrials":96,"cells":1339},"Propofol Fresenius",{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1346,"PHASE4":1348,"NA":1361},{"trials":1341,"activeCount":100},[],{"trials":1343,"activeCount":100},[],{"trials":1345,"activeCount":100},[],{"trials":1347,"activeCount":100},[],{"trials":1349,"activeCount":100},[1350],{"nctId":1351,"briefTitle":1352,"status":785,"phases":1353,"primaryCompletion":1354,"completion":956,"start":1355,"enrollment":1356,"conditions":1357,"interventions":1359},"NCT03772106","Effect of Sevoflurane and Propofol on Hepato-splanchnic Pressure and Flow During Hepatobiliary Surgery",[91],"2018-01-27","2017-06-08",29,[1358],"General Anesthesia",[1338,1360],"sevorane",{"trials":1362,"activeCount":100},[],{"intervention":1360,"totalTrials":96,"cells":1364},{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1371,"PHASE4":1373,"NA":1379},{"trials":1366,"activeCount":100},[],{"trials":1368,"activeCount":100},[],{"trials":1370,"activeCount":100},[],{"trials":1372,"activeCount":100},[],{"trials":1374,"activeCount":100},[1375],{"nctId":1351,"briefTitle":1352,"status":785,"phases":1376,"primaryCompletion":1354,"completion":956,"start":1355,"enrollment":1356,"conditions":1377,"interventions":1378},[91],[1358],[1338,1360],{"trials":1380,"activeCount":100},[],{"intervention":1382,"totalTrials":96,"cells":1383},"Sargramostim",{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1392,"NA":1405},{"trials":1385,"activeCount":100},[],{"trials":1387,"activeCount":100},[],{"trials":1389,"activeCount":100},[],{"trials":1391,"activeCount":100},[],{"trials":1393,"activeCount":100},[1394],{"nctId":1395,"briefTitle":1396,"status":785,"phases":1397,"primaryCompletion":1398,"completion":1399,"start":1400,"enrollment":1401,"conditions":1402,"interventions":1404},"NCT04326920","Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)",[91],"2020-09-28","2021-02-26","2020-03-24",87,[1403],"COVID-19",[1382],{"trials":1406,"activeCount":100},[],{"intervention":1408,"totalTrials":96,"cells":1409},"Cyclosporine A",{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1414,"PHASE3":1416,"PHASE4":1418,"NA":1431},{"trials":1411,"activeCount":100},[],{"trials":1413,"activeCount":100},[],{"trials":1415,"activeCount":100},[],{"trials":1417,"activeCount":100},[],{"trials":1419,"activeCount":100},[1420],{"nctId":1421,"briefTitle":1422,"status":785,"phases":1423,"primaryCompletion":1424,"completion":1424,"start":1425,"enrollment":1426,"conditions":1427,"interventions":1429},"NCT01211327","Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda",[91],"2008-11","2008-07",366,[1428],"Vernal Keratoconjunctivitis",[1408,1430],"Dexamethasone",{"trials":1432,"activeCount":100},[],{"intervention":1430,"totalTrials":96,"cells":1434},{"EARLY_PHASE1":1435,"PHASE1":1437,"PHASE2":1439,"PHASE3":1441,"PHASE4":1443,"NA":1449},{"trials":1436,"activeCount":100},[],{"trials":1438,"activeCount":100},[],{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":100},[],{"trials":1444,"activeCount":100},[1445],{"nctId":1421,"briefTitle":1422,"status":785,"phases":1446,"primaryCompletion":1424,"completion":1424,"start":1425,"enrollment":1426,"conditions":1447,"interventions":1448},[91],[1428],[1408,1430],{"trials":1450,"activeCount":100},[],{"intervention":1452,"totalTrials":96,"cells":1453},"1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.",{"EARLY_PHASE1":1454,"PHASE1":1456,"PHASE2":1458,"PHASE3":1460,"PHASE4":1462,"NA":1475},{"trials":1455,"activeCount":100},[],{"trials":1457,"activeCount":100},[],{"trials":1459,"activeCount":100},[],{"trials":1461,"activeCount":100},[],{"trials":1463,"activeCount":100},[1464],{"nctId":1465,"briefTitle":1466,"status":785,"phases":1467,"primaryCompletion":1468,"completion":1469,"start":1470,"enrollment":1471,"conditions":1472,"interventions":1474},"NCT02001857","Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.",[91],"2017-02","2017-08","2013-09",200,[1473],"Prostate or Bladder Cancer",[1452],{"trials":1476,"activeCount":100},[],{"intervention":1478,"totalTrials":96,"cells":1479},"Fluad",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1501},{"trials":1481,"activeCount":100},[],{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":100},[],{"trials":1489,"activeCount":100},[1490],{"nctId":1491,"briefTitle":1492,"status":785,"phases":1493,"primaryCompletion":1494,"completion":1494,"start":1495,"enrollment":1496,"conditions":1497,"interventions":1499},"NCT02523287","Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses",[91],"2016-08-01","2014-10-02",240,[1498],"Safety Markers of Adjuvanted Influenza Vaccine",[1478,1500],"Saline",{"trials":1502,"activeCount":100},[],{"intervention":1500,"totalTrials":96,"cells":1504},{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1511,"PHASE4":1513,"NA":1519},{"trials":1506,"activeCount":100},[],{"trials":1508,"activeCount":100},[],{"trials":1510,"activeCount":100},[],{"trials":1512,"activeCount":100},[],{"trials":1514,"activeCount":100},[1515],{"nctId":1491,"briefTitle":1492,"status":785,"phases":1516,"primaryCompletion":1494,"completion":1494,"start":1495,"enrollment":1496,"conditions":1517,"interventions":1518},[91],[1498],[1478,1500],{"trials":1520,"activeCount":100},[],{"intervention":1522,"totalTrials":96,"cells":1523},"Azithromycin 250 mg",{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1528,"PHASE3":1530,"PHASE4":1532,"NA":1544},{"trials":1525,"activeCount":100},[],{"trials":1527,"activeCount":100},[],{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[],{"trials":1533,"activeCount":100},[1534],{"nctId":1535,"briefTitle":1536,"status":785,"phases":1537,"primaryCompletion":834,"completion":1538,"start":1539,"enrollment":1540,"conditions":1541,"interventions":1543},"NCT00760838","AZISAST Study: AZIthromycin in Severe ASThma Study",[91],"2011-09","2009-03",109,[1542],"Asthma",[1522],{"trials":1545,"activeCount":100},[],{"intervention":1547,"totalTrials":96,"cells":1548},"Seasonal,quadrivalent,influenza vaccine",{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1555,"PHASE4":1557,"NA":1569},{"trials":1550,"activeCount":100},[],{"trials":1552,"activeCount":100},[],{"trials":1554,"activeCount":100},[],{"trials":1556,"activeCount":100},[],{"trials":1558,"activeCount":100},[1559],{"nctId":1560,"briefTitle":1561,"status":785,"phases":1562,"primaryCompletion":1563,"completion":1564,"start":1565,"enrollment":9,"conditions":1566,"interventions":1568},"NCT03160118","Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults",[91],"2017-05-17","2017-06-28","2017-03-27",[1567],"Prevention of Influenza",[1547],{"trials":1570,"activeCount":100},[],{"intervention":1572,"totalTrials":96,"cells":1573},"cervarix",{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1580,"PHASE4":1582,"NA":1594},{"trials":1575,"activeCount":100},[],{"trials":1577,"activeCount":100},[],{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":100},[1584],{"nctId":1585,"briefTitle":1586,"status":785,"phases":1587,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":19,"conditions":1590,"interventions":1592},"NCT01914367","Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)",[91],"2015-09-23","2013-06-25",[1591],"Infection With Human Papillomavirus",[1572,1593],"Gardasil",{"trials":1595,"activeCount":100},[],{"intervention":1593,"totalTrials":96,"cells":1597},{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1612},{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":100},[],{"trials":1603,"activeCount":100},[],{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":100},[1608],{"nctId":1585,"briefTitle":1586,"status":785,"phases":1609,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":19,"conditions":1610,"interventions":1611},[91],[1591],[1572,1593],{"trials":1613,"activeCount":100},[],{"intervention":1615,"totalTrials":96,"cells":1616},"Mometasone Furoate",{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1621,"PHASE3":1623,"PHASE4":1625,"NA":1637},{"trials":1618,"activeCount":100},[],{"trials":1620,"activeCount":100},[],{"trials":1622,"activeCount":100},[],{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[1627],{"nctId":1628,"briefTitle":1629,"status":785,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1636},"NCT04898764","Research on Underlying Causes of Long-term Use of Nasal Decongestants and the Structured Withdrawal of the Decongestant",[91],"2025-04-30","2020-10-21",72,[1635],"Rhinitis Medicamentosa",[1615],{"trials":1638,"activeCount":100},[],{"intervention":1640,"totalTrials":96,"cells":1641},"Secukinumab",{"EARLY_PHASE1":1642,"PHASE1":1644,"PHASE2":1646,"PHASE3":1648,"PHASE4":1650,"NA":1661},{"trials":1643,"activeCount":100},[],{"trials":1645,"activeCount":100},[],{"trials":1647,"activeCount":100},[],{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[1652],{"nctId":1653,"briefTitle":1654,"status":785,"phases":1655,"primaryCompletion":1656,"completion":1657,"start":1658,"enrollment":27,"conditions":1659,"interventions":1660},"NCT05676333","Secukinumab in Active Non-segmental Vitiligo",[91],"2017-12-16","2019-02-22","2016-10-12",[1075,1640],[1640],{"trials":1662,"activeCount":100},[],{"intervention":1664,"totalTrials":96,"cells":1665},"Dobutamine Hydrochloride",{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1670,"PHASE3":1672,"PHASE4":1674,"NA":1685},{"trials":1667,"activeCount":100},[],{"trials":1669,"activeCount":100},[],{"trials":1671,"activeCount":100},[],{"trials":1673,"activeCount":100},[],{"trials":1675,"activeCount":100},[1676],{"nctId":1677,"briefTitle":1678,"status":785,"phases":1679,"primaryCompletion":1680,"completion":1681,"start":1682,"enrollment":296,"conditions":1683,"interventions":1684},"NCT04893655","Effect of Dobutamine on Hepatic Blood Flow During Goal-directed Hemodynamic Therapy",[91],"2023-07-24","2023-07-25","2021-09-14",[1358],[1664],{"trials":1686,"activeCount":100},[],{"intervention":1688,"totalTrials":96,"cells":1689},"ciprofloxacin",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1696,"PHASE4":1698,"NA":1712},{"trials":1691,"activeCount":100},[],{"trials":1693,"activeCount":100},[],{"trials":1695,"activeCount":100},[],{"trials":1697,"activeCount":100},[],{"trials":1699,"activeCount":100},[1700],{"nctId":1701,"briefTitle":1702,"status":785,"phases":1703,"primaryCompletion":1704,"completion":1705,"start":1706,"enrollment":1707,"conditions":1708,"interventions":1711},"NCT02598362","Pharmacokinetics of Ciprofloxacin in Pediatric Patients",[91],"2017-05","2017-10","2015-04",22,[1709,1710],"Urinary Tract Infection","Pyelonephritis",[1688],{"trials":1713,"activeCount":100},[],{"intervention":1715,"totalTrials":96,"cells":1716},"Chloroprocaine 1% Injectable Solution",{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1723,"PHASE4":1725,"NA":1736},{"trials":1718,"activeCount":100},[],{"trials":1720,"activeCount":100},[],{"trials":1722,"activeCount":100},[],{"trials":1724,"activeCount":100},[],{"trials":1726,"activeCount":100},[1727],{"nctId":1728,"briefTitle":1729,"status":785,"phases":1730,"primaryCompletion":1731,"completion":956,"start":1732,"enrollment":19,"conditions":1733,"interventions":1735},"NCT03805503","Chloroprocaine for Inguinal Herniorrhaphy",[91],"2017-09-07","2015-09-16",[1734],"Spinal Anesthesia",[1715],{"trials":1737,"activeCount":100},[],{"intervention":1739,"totalTrials":96,"cells":1740},"Boostrix",{"EARLY_PHASE1":1741,"PHASE1":1743,"PHASE2":1745,"PHASE3":1747,"PHASE4":1749,"NA":1761},{"trials":1742,"activeCount":100},[],{"trials":1744,"activeCount":100},[],{"trials":1746,"activeCount":100},[],{"trials":1748,"activeCount":100},[],{"trials":1750,"activeCount":100},[1751],{"nctId":1752,"briefTitle":1753,"status":785,"phases":1754,"primaryCompletion":1755,"completion":1756,"start":1757,"enrollment":1496,"conditions":1758,"interventions":1760},"NCT02555540","Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune Responses",[91],"2015-12-15","2016-12-15","2015-08-24",[1759],"Prevention of Infections With Bordetella Pertussis",[1739],{"trials":1762,"activeCount":100},[],{"intervention":1764,"totalTrials":96,"cells":1765},"remifentanil injected",{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1770,"PHASE3":1772,"PHASE4":1774,"NA":1787},{"trials":1767,"activeCount":100},[],{"trials":1769,"activeCount":100},[],{"trials":1771,"activeCount":100},[],{"trials":1773,"activeCount":100},[],{"trials":1775,"activeCount":100},[1776],{"nctId":1777,"briefTitle":1778,"status":832,"phases":1779,"primaryCompletion":1780,"completion":1780,"start":1781,"enrollment":1782,"conditions":1783,"interventions":1785},"NCT01103193","Nitrous Oxide - Sevoflurane-Remifentanil Interaction",[91],"2010-05","2010-02",4,[1784],"ASA Class I\u002FII Patients Scheduled for Surgery Under General Anesthesia",[1764,1786],"sevoflurane in step up concentration",{"trials":1788,"activeCount":100},[],{"intervention":1786,"totalTrials":96,"cells":1790},{"EARLY_PHASE1":1791,"PHASE1":1793,"PHASE2":1795,"PHASE3":1797,"PHASE4":1799,"NA":1805},{"trials":1792,"activeCount":100},[],{"trials":1794,"activeCount":100},[],{"trials":1796,"activeCount":100},[],{"trials":1798,"activeCount":100},[],{"trials":1800,"activeCount":100},[1801],{"nctId":1777,"briefTitle":1778,"status":832,"phases":1802,"primaryCompletion":1780,"completion":1780,"start":1781,"enrollment":1782,"conditions":1803,"interventions":1804},[91],[1784],[1764,1786],{"trials":1806,"activeCount":100},[],{"intervention":1808,"totalTrials":96,"cells":1809},"Sufentanil Sublingual",{"EARLY_PHASE1":1810,"PHASE1":1812,"PHASE2":1814,"PHASE3":1816,"PHASE4":1818,"NA":1828},{"trials":1811,"activeCount":100},[],{"trials":1813,"activeCount":100},[],{"trials":1815,"activeCount":100},[],{"trials":1817,"activeCount":100},[],{"trials":1819,"activeCount":100},[1820],{"nctId":1821,"briefTitle":1822,"status":785,"phases":1823,"primaryCompletion":1824,"completion":1825,"start":381,"enrollment":442,"conditions":1826,"interventions":1827},"NCT04432428","Safety and Efficacy of Patient Controlled Analgesia Using the Sublingual Sufentanil Tablet System (SSTS) in a Fast Track Rehabilitation Program After Total Knee Arthroplasty",[91],"2021-08-31","2021-09-19",[861],[1808],{"trials":1829,"activeCount":100},[],{"intervention":1831,"totalTrials":96,"cells":1832},"sequential drug adjustment",{"EARLY_PHASE1":1833,"PHASE1":1835,"PHASE2":1837,"PHASE3":1839,"PHASE4":1841,"NA":1852},{"trials":1834,"activeCount":100},[],{"trials":1836,"activeCount":100},[],{"trials":1838,"activeCount":100},[],{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":100},[1843],{"nctId":1844,"briefTitle":1845,"status":785,"phases":1846,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":16,"conditions":1849,"interventions":1851},"NCT02389218","A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF",[91],"2020-05-14","2015-03-03",[1850],"Atrial Fibrillation",[1831],{"trials":1853,"activeCount":100},[],{"intervention":962,"totalTrials":96,"cells":1855},{"EARLY_PHASE1":1856,"PHASE1":1858,"PHASE2":1860,"PHASE3":1862,"PHASE4":1864,"NA":1870},{"trials":1857,"activeCount":100},[],{"trials":1859,"activeCount":100},[],{"trials":1861,"activeCount":100},[],{"trials":1863,"activeCount":100},[],{"trials":1865,"activeCount":100},[1866],{"nctId":952,"briefTitle":953,"status":785,"phases":1867,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1868,"interventions":1869},[91],[960],[962,939],{"trials":1871,"activeCount":100},[],{"intervention":1873,"totalTrials":96,"cells":1874},"A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation",{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1879,"PHASE3":1881,"PHASE4":1883,"NA":1900},{"trials":1876,"activeCount":100},[],{"trials":1878,"activeCount":100},[],{"trials":1880,"activeCount":100},[],{"trials":1882,"activeCount":100},[],{"trials":1884,"activeCount":100},[1885],{"nctId":1886,"briefTitle":1887,"status":1888,"phases":1889,"primaryCompletion":1890,"completion":1891,"start":1892,"enrollment":1893,"conditions":1894,"interventions":1898},"NCT04487925","Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor Responders","UNKNOWN",[91],"2024-09-30","2024-12-31","2022-01-25",208,[1895,1896,1897],"Ovarian Reserve","Poor Responders","IVF",[1873,1899],"Up to three modified natural cycles with Follitropin beta.",{"trials":1901,"activeCount":100},[],{"intervention":1899,"totalTrials":96,"cells":1903},{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1908,"PHASE3":1910,"PHASE4":1912,"NA":1918},{"trials":1905,"activeCount":100},[],{"trials":1907,"activeCount":100},[],{"trials":1909,"activeCount":100},[],{"trials":1911,"activeCount":100},[],{"trials":1913,"activeCount":100},[1914],{"nctId":1886,"briefTitle":1887,"status":1888,"phases":1915,"primaryCompletion":1890,"completion":1891,"start":1892,"enrollment":1893,"conditions":1916,"interventions":1917},[91],[1895,1896,1897],[1873,1899],{"trials":1919,"activeCount":100},[],{"intervention":1921,"totalTrials":96,"cells":1922},"Treatment with Botox",{"EARLY_PHASE1":1923,"PHASE1":1925,"PHASE2":1927,"PHASE3":1929,"PHASE4":1931,"NA":1943},{"trials":1924,"activeCount":100},[],{"trials":1926,"activeCount":100},[],{"trials":1928,"activeCount":100},[],{"trials":1930,"activeCount":100},[],{"trials":1932,"activeCount":100},[1933],{"nctId":1934,"briefTitle":1935,"status":832,"phases":1936,"primaryCompletion":1937,"completion":1937,"start":1938,"enrollment":1939,"conditions":1940,"interventions":1942},"NCT00669474","Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.",[91],"2011-08","2009-06",25,[1941],"Essential Axillary Hyperhidrosis",[1921],{"trials":1944,"activeCount":100},[],{"intervention":974,"totalTrials":96,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1955,"NA":1961},{"trials":1948,"activeCount":100},[],{"trials":1950,"activeCount":100},[],{"trials":1952,"activeCount":100},[],{"trials":1954,"activeCount":100},[],{"trials":1956,"activeCount":100},[1957],{"nctId":964,"briefTitle":965,"status":785,"phases":1958,"primaryCompletion":967,"completion":968,"start":969,"enrollment":970,"conditions":1959,"interventions":1960},[91],[972],[939,974],{"trials":1962,"activeCount":100},[],{"intervention":1964,"totalTrials":96,"cells":1965},"Low dose of alfentanil hydrochloride",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1972,"PHASE4":1974,"NA":1985},{"trials":1967,"activeCount":100},[],{"trials":1969,"activeCount":100},[],{"trials":1971,"activeCount":100},[],{"trials":1973,"activeCount":100},[],{"trials":1975,"activeCount":100},[1976],{"nctId":1977,"briefTitle":1978,"status":1044,"phases":1979,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":100,"conditions":1982,"interventions":1983},"NCT00742807","Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols",[91],"2015-05","2008-08",[1314],[1964,1984],"Normal dose of alfentanil hydrochloride",{"trials":1986,"activeCount":100},[],{"intervention":1984,"totalTrials":96,"cells":1988},{"EARLY_PHASE1":1989,"PHASE1":1991,"PHASE2":1993,"PHASE3":1995,"PHASE4":1997,"NA":2003},{"trials":1990,"activeCount":100},[],{"trials":1992,"activeCount":100},[],{"trials":1994,"activeCount":100},[],{"trials":1996,"activeCount":100},[],{"trials":1998,"activeCount":100},[1999],{"nctId":1977,"briefTitle":1978,"status":1044,"phases":2000,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":100,"conditions":2001,"interventions":2002},[91],[1314],[1964,1984],{"trials":2004,"activeCount":100},[],{"intervention":2006,"totalTrials":96,"cells":2007},"Tisseel®",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2014,"PHASE4":2016,"NA":2029},{"trials":2009,"activeCount":100},[],{"trials":2011,"activeCount":100},[],{"trials":2013,"activeCount":100},[],{"trials":2015,"activeCount":100},[],{"trials":2017,"activeCount":100},[2018],{"nctId":2019,"briefTitle":2020,"status":785,"phases":2021,"primaryCompletion":2022,"completion":2023,"start":2024,"enrollment":2025,"conditions":2026,"interventions":2028},"NCT00775034","Drainage Versus Sealant in Double Blinded Monocentric Open Incisional Hernia Repair",[91],"2014-10-14","2018-05-24","2010-01-27",57,[2027],"Incisional Hernia",[2006],{"trials":2030,"activeCount":100},[],{"intervention":2032,"totalTrials":96,"cells":2033},"Fentanyl dosing schemes",{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2040,"PHASE4":2042,"NA":2058},{"trials":2035,"activeCount":100},[],{"trials":2037,"activeCount":100},[],{"trials":2039,"activeCount":100},[],{"trials":2041,"activeCount":100},[],{"trials":2043,"activeCount":100},[2044],{"nctId":2045,"briefTitle":2046,"status":785,"phases":2047,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":2052,"interventions":2057},"NCT03450161","Hyperalgesia, Persistent Pain, and Fentanyl Dosing in On-Pump Coronary Artery Bypass Grafting",[91],"2020-02-01","2021-01-09","2018-05-14",80,[2053,2054,2055,2056],"Hyperalgesia","Opioid Use","Pain, Postoperative","Pain, Chronic",[2032],{"trials":2059,"activeCount":100},[],{"intervention":2061,"totalTrials":96,"cells":2062},"Letrozole",{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2069,"PHASE4":2071,"NA":2080},{"trials":2064,"activeCount":100},[],{"trials":2066,"activeCount":100},[],{"trials":2068,"activeCount":100},[],{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":100},[2073],{"nctId":2074,"briefTitle":2075,"status":785,"phases":2076,"primaryCompletion":1046,"completion":1046,"start":2077,"enrollment":996,"conditions":2078,"interventions":2079},"NCT02097680","Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men",[91],"2013-12",[922],[2061],{"trials":2081,"activeCount":100},[],{"intervention":2083,"totalTrials":96,"cells":2084},"Tilmanocept",{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2089,"PHASE3":2091,"PHASE4":2093,"NA":2105},{"trials":2086,"activeCount":100},[],{"trials":2088,"activeCount":100},[],{"trials":2090,"activeCount":100},[],{"trials":2092,"activeCount":100},[],{"trials":2094,"activeCount":100},[2095],{"nctId":2096,"briefTitle":2097,"status":1044,"phases":2098,"primaryCompletion":2099,"completion":2099,"start":2100,"enrollment":100,"conditions":2101,"interventions":2103},"NCT04487912","Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer",[91],"2021-05-01","2020-11-24",[31,2102],"Sentinel Lymph Node",[2083,2104],"Nanocolloid",{"trials":2106,"activeCount":100},[],{"intervention":2104,"totalTrials":96,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2115,"PHASE4":2117,"NA":2123},{"trials":2110,"activeCount":100},[],{"trials":2112,"activeCount":100},[],{"trials":2114,"activeCount":100},[],{"trials":2116,"activeCount":100},[],{"trials":2118,"activeCount":100},[2119],{"nctId":2096,"briefTitle":2097,"status":1044,"phases":2120,"primaryCompletion":2099,"completion":2099,"start":2100,"enrollment":100,"conditions":2121,"interventions":2122},[91],[31,2102],[2083,2104],{"trials":2124,"activeCount":100},[],{"intervention":2126,"totalTrials":96,"cells":2127},"Myo-inositol",{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2132,"PHASE3":2134,"PHASE4":2136,"NA":2152},{"trials":2129,"activeCount":100},[],{"trials":2131,"activeCount":100},[],{"trials":2133,"activeCount":100},[],{"trials":2135,"activeCount":100},[],{"trials":2137,"activeCount":100},[2138],{"nctId":2139,"briefTitle":2140,"status":832,"phases":2141,"primaryCompletion":2142,"completion":2143,"start":2144,"enrollment":19,"conditions":2145,"interventions":2150},"NCT04306692","Myo-inositol Versus Clomiphene Citrate in PCOS",[91],"2021-04-20","2022-01-31","2020-07-02",[2146,2147,2148,2149],"Ovulation Induction","Polycystic Ovary Syndrome","Clomiphene","Inositol",[2126,2151],"Clomiphene Citrate",{"trials":2153,"activeCount":100},[],{"intervention":2151,"totalTrials":96,"cells":2155},{"EARLY_PHASE1":2156,"PHASE1":2158,"PHASE2":2160,"PHASE3":2162,"PHASE4":2164,"NA":2170},{"trials":2157,"activeCount":100},[],{"trials":2159,"activeCount":100},[],{"trials":2161,"activeCount":100},[],{"trials":2163,"activeCount":100},[],{"trials":2165,"activeCount":100},[2166],{"nctId":2139,"briefTitle":2140,"status":832,"phases":2167,"primaryCompletion":2142,"completion":2143,"start":2144,"enrollment":19,"conditions":2168,"interventions":2169},[91],[2146,2147,2148,2149],[2126,2151],{"trials":2171,"activeCount":100},[],{"intervention":2173,"totalTrials":96,"cells":2174},"Spinal administration of chloroprocaine.",{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2181,"PHASE4":2183,"NA":2195},{"trials":2176,"activeCount":100},[],{"trials":2178,"activeCount":100},[],{"trials":2180,"activeCount":100},[],{"trials":2182,"activeCount":100},[],{"trials":2184,"activeCount":100},[2185],{"nctId":2186,"briefTitle":2187,"status":785,"phases":2188,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":1245,"conditions":2192,"interventions":2194},"NCT01909089","Determination of the Minimum Local Analgesic Dose of Spinal Chloroprocaine in Labour",[91],"2015-08-21","2017-10-18","2013-10-17",[2193],"Pain Relief During Labour",[2173],{"trials":2196,"activeCount":100},[],{"intervention":2198,"totalTrials":96,"cells":2199},"individual adapted immunosuppression",{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2208,"NA":2222},{"trials":2201,"activeCount":100},[],{"trials":2203,"activeCount":100},[],{"trials":2205,"activeCount":100},[],{"trials":2207,"activeCount":100},[],{"trials":2209,"activeCount":100},[2210],{"nctId":2211,"briefTitle":2212,"status":785,"phases":2213,"primaryCompletion":2214,"completion":2215,"start":2216,"enrollment":2217,"conditions":2218,"interventions":2220},"NCT00895206","Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study",[91],"2016-08","2016-10","2009-05",128,[2219],"Kidney Transplantation",[2198,2221],"golden standard therapy",{"trials":2223,"activeCount":100},[],{"intervention":2221,"totalTrials":96,"cells":2225},{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2232,"PHASE4":2234,"NA":2240},{"trials":2227,"activeCount":100},[],{"trials":2229,"activeCount":100},[],{"trials":2231,"activeCount":100},[],{"trials":2233,"activeCount":100},[],{"trials":2235,"activeCount":100},[2236],{"nctId":2211,"briefTitle":2212,"status":785,"phases":2237,"primaryCompletion":2214,"completion":2215,"start":2216,"enrollment":2217,"conditions":2238,"interventions":2239},[91],[2219],[2198,2221],{"trials":2241,"activeCount":100},[],{"intervention":815,"totalTrials":96,"cells":2243},{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2250,"PHASE4":2252,"NA":2258},{"trials":2245,"activeCount":100},[],{"trials":2247,"activeCount":100},[],{"trials":2249,"activeCount":100},[],{"trials":2251,"activeCount":100},[],{"trials":2253,"activeCount":100},[2254],{"nctId":804,"briefTitle":805,"status":785,"phases":2255,"primaryCompletion":807,"completion":807,"start":808,"enrollment":809,"conditions":2256,"interventions":2257},[91],[811,812],[814,815],{"trials":2259,"activeCount":100},[],{"intervention":2261,"totalTrials":96,"cells":2262},"Norepinephrine",{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2267,"PHASE3":2269,"PHASE4":2271,"NA":2283},{"trials":2264,"activeCount":100},[],{"trials":2266,"activeCount":100},[],{"trials":2268,"activeCount":100},[],{"trials":2270,"activeCount":100},[],{"trials":2272,"activeCount":100},[2273],{"nctId":2274,"briefTitle":2275,"status":785,"phases":2276,"primaryCompletion":2277,"completion":2278,"start":2279,"enrollment":2280,"conditions":2281,"interventions":2282},"NCT03965117","Effect of Norepinephrine Infusion on Hepatic Blood Flow During Goal-directed Haemodynamic Therapy.",[91],"2020-10-22","2022-10-14","2019-05-28",49,[1358],[2261],{"trials":2284,"activeCount":100},[],{"intervention":2286,"totalTrials":96,"cells":2287},"Bevacizumab Injection [Avastin]",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2296,"NA":2308},{"trials":2289,"activeCount":100},[],{"trials":2291,"activeCount":100},[],{"trials":2293,"activeCount":100},[],{"trials":2295,"activeCount":100},[],{"trials":2297,"activeCount":100},[2298],{"nctId":2299,"briefTitle":2300,"status":1888,"phases":2301,"primaryCompletion":1891,"completion":1891,"start":2302,"enrollment":2303,"conditions":2304,"interventions":2307},"NCT03211741","Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema",[91],"2013-11-22",500,[2305,2306],"Retinal Neovascularization","Macular Edema",[2286],{"trials":2309,"activeCount":100},[],{"intervention":2311,"totalTrials":96,"cells":2312},"Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels",{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2317,"PHASE3":2319,"PHASE4":2321,"NA":2332},{"trials":2314,"activeCount":100},[],{"trials":2316,"activeCount":100},[],{"trials":2318,"activeCount":100},[],{"trials":2320,"activeCount":100},[],{"trials":2322,"activeCount":100},[2323],{"nctId":2324,"briefTitle":2325,"status":785,"phases":2326,"primaryCompletion":1287,"completion":2327,"start":2328,"enrollment":1156,"conditions":2329,"interventions":2331},"NCT05683054","A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated",[91],"2022-08-22","2020-08-11",[2330],"Psoriasis",[2311],{"trials":2333,"activeCount":100},[],{"intervention":2335,"totalTrials":96,"cells":2336},"Standard Injection of Levobupivacaine in portal sites.",{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2343,"PHASE4":2345,"NA":2359},{"trials":2338,"activeCount":100},[],{"trials":2340,"activeCount":100},[],{"trials":2342,"activeCount":100},[],{"trials":2344,"activeCount":100},[],{"trials":2346,"activeCount":100},[2347],{"nctId":2348,"briefTitle":2349,"status":785,"phases":2350,"primaryCompletion":2351,"completion":2352,"start":2353,"enrollment":2354,"conditions":2355,"interventions":2356},"NCT01886352","Intraperitoneal Atomization of Levobupivacaine During Gynaecological Laparoscopic Procedures ; Impact on Pain, Opioid Use and Length of Recovery Room Stay (IPLA).",[91],"2014-06-13","2018-12-03","2013-06-26",16,[2055],[2335,2357,2358],"Additional injection of 0,5% levobupivacaine.","Intraperitoneal atomization of levobupivacaine.",{"trials":2360,"activeCount":100},[],{"intervention":2357,"totalTrials":96,"cells":2362},{"EARLY_PHASE1":2363,"PHASE1":2365,"PHASE2":2367,"PHASE3":2369,"PHASE4":2371,"NA":2377},{"trials":2364,"activeCount":100},[],{"trials":2366,"activeCount":100},[],{"trials":2368,"activeCount":100},[],{"trials":2370,"activeCount":100},[],{"trials":2372,"activeCount":100},[2373],{"nctId":2348,"briefTitle":2349,"status":785,"phases":2374,"primaryCompletion":2351,"completion":2352,"start":2353,"enrollment":2354,"conditions":2375,"interventions":2376},[91],[2055],[2335,2357,2358],{"trials":2378,"activeCount":100},[],{"intervention":2358,"totalTrials":96,"cells":2380},{"EARLY_PHASE1":2381,"PHASE1":2383,"PHASE2":2385,"PHASE3":2387,"PHASE4":2389,"NA":2395},{"trials":2382,"activeCount":100},[],{"trials":2384,"activeCount":100},[],{"trials":2386,"activeCount":100},[],{"trials":2388,"activeCount":100},[],{"trials":2390,"activeCount":100},[2391],{"nctId":2348,"briefTitle":2349,"status":785,"phases":2392,"primaryCompletion":2351,"completion":2352,"start":2353,"enrollment":2354,"conditions":2393,"interventions":2394},[91],[2055],[2335,2357,2358],{"trials":2396,"activeCount":100},[],{"intervention":2398,"totalTrials":96,"cells":2399},"ticagrelor",{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2406,"PHASE4":2408,"NA":2419},{"trials":2401,"activeCount":100},[],{"trials":2403,"activeCount":100},[],{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"trials":2409,"activeCount":100},[2410],{"nctId":2411,"briefTitle":2412,"status":785,"phases":2413,"primaryCompletion":2414,"completion":2414,"start":2415,"enrollment":1245,"conditions":2416,"interventions":2418},"NCT02341729","Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome",[91],"2019-12","2015-03",[2417],"Acute Coronary Syndrome",[2398],{"trials":2420,"activeCount":100},[],{"intervention":2422,"totalTrials":96,"cells":2423},"injection in the knee joint with 20 ml of chirocaine 0.125%",{"EARLY_PHASE1":2424,"PHASE1":2426,"PHASE2":2428,"PHASE3":2430,"PHASE4":2432,"NA":2444},{"trials":2425,"activeCount":100},[],{"trials":2427,"activeCount":100},[],{"trials":2429,"activeCount":100},[],{"trials":2431,"activeCount":100},[],{"trials":2433,"activeCount":100},[2434],{"nctId":2435,"briefTitle":2436,"status":785,"phases":2437,"primaryCompletion":2438,"completion":2438,"start":2439,"enrollment":116,"conditions":2440,"interventions":2442},"NCT00620477","Evaluation of Arthroscopic Reconstruction of the Anterior Cruciate Ligament by One Night Hospital Stay or by Day Surgery: a Randomised, Prospective Clinical Trial",[91],"2010-11-03","2008-07-30",[2441],"Rupture of the Anterior Cruciate Ligament With Instability of the Knee Joint",[2422,2443],"injection in the knee joint with 20 ml of physiological fluid",{"trials":2445,"activeCount":100},[],{"intervention":2443,"totalTrials":96,"cells":2447},{"EARLY_PHASE1":2448,"PHASE1":2450,"PHASE2":2452,"PHASE3":2454,"PHASE4":2456,"NA":2462},{"trials":2449,"activeCount":100},[],{"trials":2451,"activeCount":100},[],{"trials":2453,"activeCount":100},[],{"trials":2455,"activeCount":100},[],{"trials":2457,"activeCount":100},[2458],{"nctId":2435,"briefTitle":2436,"status":785,"phases":2459,"primaryCompletion":2438,"completion":2438,"start":2439,"enrollment":116,"conditions":2460,"interventions":2461},[91],[2441],[2422,2443],{"trials":2463,"activeCount":100},[],{"intervention":2465,"totalTrials":868,"cells":2466},"aspirin",{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2471,"PHASE3":2490,"PHASE4":2502,"NA":2504},{"trials":2468,"activeCount":100},[],{"trials":2470,"activeCount":100},[],{"trials":2472,"activeCount":100},[2473],{"nctId":2474,"briefTitle":2475,"status":785,"phases":2476,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":2479,"conditions":2480,"interventions":2484},"NCT03192059","Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical\u002FUterine Cancer",[89],"2021-06-30","2017-07-01",43,[2481,2482,2483],"Cervical Cancer","Endometrial Cancer","Uterine Cancer",[2485,2486,2487,2488,2489],"Pembrolizumab","Vitamin D","Aspirin","Lansoprazole","Cyclophosphamide",{"trials":2491,"activeCount":100},[2492],{"nctId":2493,"briefTitle":2494,"status":785,"phases":2495,"completion":2496,"start":2497,"enrollment":2498,"conditions":2499,"interventions":2501},"NCT00644085","Does Low-Dose Aspirin Improve Outcome in In Vitro Fertilisation\u002FIntra Cytoplasmatic Sperm Injection (IVF\u002FICSI)?",[90],"2007-12","2000-04",201,[2500],"Infertility",[2465],{"trials":2503,"activeCount":100},[],{"trials":2505,"activeCount":100},[],{"intervention":2507,"totalTrials":96,"cells":2508},"Lanreotide Autogel 120mg",{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2513,"PHASE3":2515,"PHASE4":2526,"NA":2528},{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[],{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[2517],{"nctId":2518,"briefTitle":2519,"status":785,"phases":2520,"primaryCompletion":2521,"completion":2521,"start":2522,"enrollment":809,"conditions":2523,"interventions":2525},"NCT01372007","Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma",[90],"2014-12","2011-07",[2524],"Rectal Carcinoma",[2507],{"trials":2527,"activeCount":100},[],{"trials":2529,"activeCount":100},[],{"intervention":2531,"totalTrials":96,"cells":2532},"Gabapentin",{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2539,"PHASE4":2552,"NA":2554},{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[],{"trials":2540,"activeCount":100},[2541],{"nctId":2542,"briefTitle":2543,"status":1044,"phases":2544,"primaryCompletion":2545,"completion":2545,"start":2546,"enrollment":100,"conditions":2547,"interventions":2551},"NCT03747562","Study of Efficacy and Safety of Gabapentin to Reduce the Need for Strong Opioid Use in Head and Neck Cancer Patients.",[90],"2022-07-01","2019-03-01",[2548,2549,2550],"Head Neck Cancer","Radiation Neuropathy","Pain, Neuropathic",[2531],{"trials":2553,"activeCount":100},[],{"trials":2555,"activeCount":100},[],{"intervention":2557,"totalTrials":96,"cells":2558},"Anakinra",{"EARLY_PHASE1":2559,"PHASE1":2561,"PHASE2":2563,"PHASE3":2565,"PHASE4":2579,"NA":2581},{"trials":2560,"activeCount":100},[],{"trials":2562,"activeCount":100},[],{"trials":2564,"activeCount":100},[],{"trials":2566,"activeCount":100},[2567],{"nctId":2568,"briefTitle":2569,"status":785,"phases":2570,"primaryCompletion":2571,"completion":2572,"start":2573,"enrollment":2574,"conditions":2575,"interventions":2576},"NCT04330638","Treatment of COVID-19 Patients With Anti-interleukin Drugs",[90],"2020-12-20","2021-05-21","2020-04-03",342,[1403],[2557,2577,2578],"Siltuximab","Tocilizumab",{"trials":2580,"activeCount":100},[],{"trials":2582,"activeCount":100},[],{"intervention":2577,"totalTrials":96,"cells":2584},{"EARLY_PHASE1":2585,"PHASE1":2587,"PHASE2":2589,"PHASE3":2591,"PHASE4":2597,"NA":2599},{"trials":2586,"activeCount":100},[],{"trials":2588,"activeCount":100},[],{"trials":2590,"activeCount":100},[],{"trials":2592,"activeCount":100},[2593],{"nctId":2568,"briefTitle":2569,"status":785,"phases":2594,"primaryCompletion":2571,"completion":2572,"start":2573,"enrollment":2574,"conditions":2595,"interventions":2596},[90],[1403],[2557,2577,2578],{"trials":2598,"activeCount":100},[],{"trials":2600,"activeCount":100},[],{"intervention":2578,"totalTrials":96,"cells":2602},{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2609,"PHASE4":2615,"NA":2617},{"trials":2604,"activeCount":100},[],{"trials":2606,"activeCount":100},[],{"trials":2608,"activeCount":100},[],{"trials":2610,"activeCount":100},[2611],{"nctId":2568,"briefTitle":2569,"status":785,"phases":2612,"primaryCompletion":2571,"completion":2572,"start":2573,"enrollment":2574,"conditions":2613,"interventions":2614},[90],[1403],[2557,2577,2578],{"trials":2616,"activeCount":100},[],{"trials":2618,"activeCount":100},[],{"intervention":2620,"totalTrials":96,"cells":2621},"administration of Cimzia®",{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2626,"PHASE3":2628,"PHASE4":2643,"NA":2645},{"trials":2623,"activeCount":100},[],{"trials":2625,"activeCount":100},[],{"trials":2627,"activeCount":100},[],{"trials":2629,"activeCount":100},[2630],{"nctId":2631,"briefTitle":2632,"status":785,"phases":2633,"primaryCompletion":2634,"completion":2635,"start":2636,"enrollment":2637,"conditions":2638,"interventions":2641},"NCT01590966","Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis",[90],"2019-03-26","2019-08-20","2012-10-18",41,[2639,2640],"Axial and Peripheral Spondyloarthritis","Rheumatoid Arthritis",[2620,2642],"Immunoscintigraphy with radiolabeled Cimzia®.",{"trials":2644,"activeCount":100},[],{"trials":2646,"activeCount":100},[],{"intervention":2642,"totalTrials":96,"cells":2648},{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2653,"PHASE3":2655,"PHASE4":2661,"NA":2663},{"trials":2650,"activeCount":100},[],{"trials":2652,"activeCount":100},[],{"trials":2654,"activeCount":100},[],{"trials":2656,"activeCount":100},[2657],{"nctId":2631,"briefTitle":2632,"status":785,"phases":2658,"primaryCompletion":2634,"completion":2635,"start":2636,"enrollment":2637,"conditions":2659,"interventions":2660},[90],[2639,2640],[2620,2642],{"trials":2662,"activeCount":100},[],{"trials":2664,"activeCount":100},[],{"intervention":2666,"totalTrials":96,"cells":2667},"Losartan",{"EARLY_PHASE1":2668,"PHASE1":2670,"PHASE2":2672,"PHASE3":2674,"PHASE4":2685,"NA":2687},{"trials":2669,"activeCount":100},[],{"trials":2671,"activeCount":100},[],{"trials":2673,"activeCount":100},[],{"trials":2675,"activeCount":100},[2676],{"nctId":2677,"briefTitle":2678,"status":785,"phases":2679,"primaryCompletion":2680,"completion":2680,"start":2681,"enrollment":1707,"conditions":2682,"interventions":2684},"NCT00782327","Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers",[90],"2014-11-26","2009-11-01",[2683],"Marfan Syndrome",[2666],{"trials":2686,"activeCount":100},[],{"trials":2688,"activeCount":100},[],{"intervention":2690,"totalTrials":96,"cells":2691},"Progesteron TID",{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2696,"PHASE3":2698,"PHASE4":2711,"NA":2713},{"trials":2693,"activeCount":100},[],{"trials":2695,"activeCount":100},[],{"trials":2697,"activeCount":100},[],{"trials":2699,"activeCount":100},[2700],{"nctId":2701,"briefTitle":2702,"status":785,"phases":2703,"primaryCompletion":2704,"completion":2705,"start":2706,"enrollment":1401,"conditions":2707,"interventions":2710},"NCT04806919","Luteal Support in Artificial Vitrified\u002FWarmed Cycles With Low Progesterone",[90],"2025-02-28","2025-03-31","2021-04-02",[1897,2708,2709],"Embryo Loss","Luteal Phase Defect",[2690],{"trials":2712,"activeCount":100},[],{"trials":2714,"activeCount":100},[],{"intervention":2716,"totalTrials":96,"cells":2717},"diuretics",{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2722,"PHASE3":2724,"PHASE4":2735,"NA":2737},{"trials":2719,"activeCount":100},[],{"trials":2721,"activeCount":100},[],{"trials":2723,"activeCount":100},[],{"trials":2725,"activeCount":100},[2726],{"nctId":2727,"briefTitle":2728,"status":785,"phases":2729,"primaryCompletion":2730,"completion":2731,"start":1781,"enrollment":96,"conditions":2732,"interventions":2734},"NCT01138683","Cardiorenal Interactions During Treatment of Acute Decompensated Heart Failure: Diuretics Versus Ultrafiltration",[90],"2011-10","2011-12",[2733],"Acute Decompensated Heart Failure",[2716],{"trials":2736,"activeCount":100},[],{"trials":2738,"activeCount":100},[],{"intervention":2740,"totalTrials":96,"cells":2741},"Golimumab",{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2746,"PHASE3":2748,"PHASE4":2760,"NA":2762},{"trials":2743,"activeCount":100},[],{"trials":2745,"activeCount":100},[],{"trials":2747,"activeCount":100},[],{"trials":2749,"activeCount":100},[2750],{"nctId":2751,"briefTitle":2752,"status":785,"phases":2753,"primaryCompletion":2754,"completion":2755,"start":2756,"enrollment":116,"conditions":2757,"interventions":2759},"NCT01426815","Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria",[90],"2019-03","2019-03-18","2012-03-13",[2758],"Peripheral Spondylarthritis",[2740],{"trials":2761,"activeCount":100},[],{"trials":2763,"activeCount":100},[],{"intervention":2765,"totalTrials":868,"cells":2766},"Administration of placebo",{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2780,"PHASE3":2791,"PHASE4":2793,"NA":2795},{"trials":2768,"activeCount":100},[],{"trials":2770,"activeCount":100},[2771],{"nctId":2772,"briefTitle":2773,"status":785,"phases":2774,"primaryCompletion":2077,"completion":2775,"start":1154,"enrollment":958,"conditions":2776,"interventions":2778},"NCT01290172","Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.",[88],"2014-01",[2777],"Liver Transplant With Clinically Significant Portal Hypertension",[2779,2765],"Administration of Somatostatin",{"trials":2781,"activeCount":100},[2782],{"nctId":2783,"briefTitle":2784,"status":785,"phases":2785,"primaryCompletion":1780,"completion":1780,"start":2786,"enrollment":2787,"conditions":2788,"interventions":2789},"NCT00557700","Study to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate Asthma",[89],"2008-01",15,[1542],[2790,2765],"Administration of inhaled tiotropium bromide",{"trials":2792,"activeCount":100},[],{"trials":2794,"activeCount":100},[],{"trials":2796,"activeCount":100},[],{"intervention":2489,"totalTrials":868,"cells":2798},{"EARLY_PHASE1":2799,"PHASE1":2810,"PHASE2":2812,"PHASE3":2818,"PHASE4":2820,"NA":2822},{"trials":2800,"activeCount":100},[2801],{"nctId":2802,"briefTitle":2803,"status":1044,"phases":2804,"primaryCompletion":2805,"completion":2805,"start":1706,"enrollment":100,"conditions":2806,"interventions":2809},"NCT02441270","Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients",[87],"2018-05-15",[2807,2808],"Radiotherapy","Immunology",[2489],{"trials":2811,"activeCount":100},[],{"trials":2813,"activeCount":100},[2814],{"nctId":2474,"briefTitle":2475,"status":785,"phases":2815,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":2479,"conditions":2816,"interventions":2817},[89],[2481,2482,2483],[2485,2486,2487,2488,2489],{"trials":2819,"activeCount":100},[],{"trials":2821,"activeCount":100},[],{"trials":2823,"activeCount":100},[],{"intervention":2485,"totalTrials":868,"cells":2825},{"EARLY_PHASE1":2826,"PHASE1":2828,"PHASE2":2842,"PHASE3":2848,"PHASE4":2850,"NA":2852},{"trials":2827,"activeCount":100},[],{"trials":2829,"activeCount":100},[2830],{"nctId":2831,"briefTitle":2832,"status":785,"phases":2833,"primaryCompletion":2834,"completion":2835,"start":2836,"enrollment":2837,"conditions":2838,"interventions":2840},"NCT02826564","Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer",[88],"2018-04-02","2019-02-18","2016-11-14",18,[2839],"Metastatic Urothelial Cancer",[2841],"pembrolizumab",{"trials":2843,"activeCount":100},[2844],{"nctId":2474,"briefTitle":2475,"status":785,"phases":2845,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":2479,"conditions":2846,"interventions":2847},[89],[2481,2482,2483],[2485,2486,2487,2488,2489],{"trials":2849,"activeCount":100},[],{"trials":2851,"activeCount":100},[],{"trials":2853,"activeCount":100},[],{"intervention":2855,"totalTrials":96,"cells":2856},"Application of pimecrolimus",{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2872,"PHASE4":2874,"NA":2876},{"trials":2858,"activeCount":100},[],{"trials":2860,"activeCount":100},[],{"trials":2862,"activeCount":100},[2863],{"nctId":2864,"briefTitle":2865,"status":785,"phases":2866,"completion":2867,"start":928,"enrollment":2868,"conditions":2869,"interventions":2871},"NCT00372307","Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris",[89],"2004-11",26,[2870],"Vitiligo Vulgaris",[2855],{"trials":2873,"activeCount":100},[],{"trials":2875,"activeCount":100},[],{"trials":2877,"activeCount":100},[],{"intervention":2790,"totalTrials":96,"cells":2879},{"EARLY_PHASE1":2880,"PHASE1":2882,"PHASE2":2884,"PHASE3":2890,"PHASE4":2892,"NA":2894},{"trials":2881,"activeCount":100},[],{"trials":2883,"activeCount":100},[],{"trials":2885,"activeCount":100},[2886],{"nctId":2783,"briefTitle":2784,"status":785,"phases":2887,"primaryCompletion":1780,"completion":1780,"start":2786,"enrollment":2787,"conditions":2888,"interventions":2889},[89],[1542],[2790,2765],{"trials":2891,"activeCount":100},[],{"trials":2893,"activeCount":100},[],{"trials":2895,"activeCount":100},[],{"intervention":2897,"totalTrials":96,"cells":2898},"5-HTP",{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2903,"PHASE3":2919,"PHASE4":2921,"NA":2923},{"trials":2900,"activeCount":100},[],{"trials":2902,"activeCount":100},[],{"trials":2904,"activeCount":100},[2905],{"nctId":2906,"briefTitle":2907,"status":785,"phases":2908,"primaryCompletion":2909,"completion":2910,"start":2911,"enrollment":2912,"conditions":2913,"interventions":2918},"NCT03574948","5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores",[89],"2021-02-23","2021-03-03","2018-12-06",175,[2914,2915,2916,2917],"Crohn Disease","Ulcerative Colitis","Fatigue","Remission",[2897],{"trials":2920,"activeCount":100},[],{"trials":2922,"activeCount":100},[],{"trials":2924,"activeCount":100},[],{"intervention":2926,"totalTrials":96,"cells":2927},"CMV-specific T cells",{"EARLY_PHASE1":2928,"PHASE1":2930,"PHASE2":2932,"PHASE3":2944,"PHASE4":2946,"NA":2948},{"trials":2929,"activeCount":100},[],{"trials":2931,"activeCount":100},[],{"trials":2933,"activeCount":100},[2934],{"nctId":2935,"briefTitle":2936,"status":785,"phases":2937,"primaryCompletion":2938,"completion":2938,"start":2215,"enrollment":96,"conditions":2939,"interventions":2942},"NCT03067155","CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.",[89],"2021-12-31",[2940,2941],"Hematological Malignancies","CMV Infection",[2926,2943],"Standard anti-viral therapy",{"trials":2945,"activeCount":100},[],{"trials":2947,"activeCount":100},[],{"trials":2949,"activeCount":100},[],{"intervention":2943,"totalTrials":96,"cells":2951},{"EARLY_PHASE1":2952,"PHASE1":2954,"PHASE2":2956,"PHASE3":2962,"PHASE4":2964,"NA":2966},{"trials":2953,"activeCount":100},[],{"trials":2955,"activeCount":100},[],{"trials":2957,"activeCount":100},[2958],{"nctId":2935,"briefTitle":2936,"status":785,"phases":2959,"primaryCompletion":2938,"completion":2938,"start":2215,"enrollment":96,"conditions":2960,"interventions":2961},[89],[2940,2941],[2926,2943],{"trials":2963,"activeCount":100},[],{"trials":2965,"activeCount":100},[],{"trials":2967,"activeCount":100},[],{"intervention":2969,"totalTrials":96,"cells":2970},"Administration of remifentanil and glycopyrrolate",{"EARLY_PHASE1":2971,"PHASE1":2973,"PHASE2":2975,"PHASE3":2987,"PHASE4":2989,"NA":2991},{"trials":2972,"activeCount":100},[],{"trials":2974,"activeCount":100},[],{"trials":2976,"activeCount":100},[2977],{"nctId":2978,"briefTitle":2979,"status":785,"phases":2980,"primaryCompletion":2981,"completion":2981,"start":2982,"enrollment":2983,"conditions":2984,"interventions":2986},"NCT00315536","Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children",[89],"2009-04","2006-05",63,[2985],"Urological Surgery",[2969],{"trials":2988,"activeCount":100},[],{"trials":2990,"activeCount":100},[],{"trials":2992,"activeCount":100},[],{"intervention":2994,"totalTrials":96,"cells":2995},"Administration of tramadol intravenously",{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3000,"PHASE3":3010,"PHASE4":3012,"NA":3014},{"trials":2997,"activeCount":100},[],{"trials":2999,"activeCount":100},[],{"trials":3001,"activeCount":100},[3002],{"nctId":3003,"briefTitle":3004,"status":785,"phases":3005,"primaryCompletion":2981,"completion":2981,"start":3006,"enrollment":1471,"conditions":3007,"interventions":3009},"NCT00333346","Tramadol iv. : Influence of Dose and Dose Intervals on Therapeutic Accuracy and Side Effects When Used for Postoperative Pain Relief in Ambulatory Surgery",[89],"2006-09",[3008],"Ambulatory Surgery",[2994],{"trials":3011,"activeCount":100},[],{"trials":3013,"activeCount":100},[],{"trials":3015,"activeCount":100},[],{"intervention":3017,"totalTrials":96,"cells":3018},"Administration of rituximab and methylprednisolone",{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3023,"PHASE3":3034,"PHASE4":3036,"NA":3038},{"trials":3020,"activeCount":100},[],{"trials":3022,"activeCount":100},[],{"trials":3024,"activeCount":100},[3025],{"nctId":3026,"briefTitle":3027,"status":785,"phases":3028,"primaryCompletion":3029,"completion":3029,"start":3030,"enrollment":24,"conditions":3031,"interventions":3033},"NCT00379431","A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab",[89],"2009-02-02","2006-11-27",[3032],"Early and Severe Systemic Sclerosis",[3017],{"trials":3035,"activeCount":100},[],{"trials":3037,"activeCount":100},[],{"trials":3039,"activeCount":100},[],{"intervention":3041,"totalTrials":96,"cells":3042},"nitroprusside",{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3047,"PHASE3":3060,"PHASE4":3062,"NA":3064},{"trials":3044,"activeCount":100},[],{"trials":3046,"activeCount":100},[],{"trials":3048,"activeCount":100},[3049],{"nctId":3050,"briefTitle":3051,"status":785,"phases":3052,"primaryCompletion":3053,"completion":3053,"start":3054,"enrollment":996,"conditions":3055,"interventions":3057},"NCT00535808","Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: A Randomized Study",[89],"2011-03","2007-10",[3056],"Cerebral Oxygenation",[3041,3058,3059],"nitroglycerine","sevoflurane",{"trials":3061,"activeCount":100},[],{"trials":3063,"activeCount":100},[],{"trials":3065,"activeCount":100},[],{"intervention":3058,"totalTrials":96,"cells":3067},{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3072,"PHASE3":3078,"PHASE4":3080,"NA":3082},{"trials":3069,"activeCount":100},[],{"trials":3071,"activeCount":100},[],{"trials":3073,"activeCount":100},[3074],{"nctId":3050,"briefTitle":3051,"status":785,"phases":3075,"primaryCompletion":3053,"completion":3053,"start":3054,"enrollment":996,"conditions":3076,"interventions":3077},[89],[3056],[3041,3058,3059],{"trials":3079,"activeCount":100},[],{"trials":3081,"activeCount":100},[],{"trials":3083,"activeCount":100},[],{"intervention":3059,"totalTrials":96,"cells":3085},{"EARLY_PHASE1":3086,"PHASE1":3088,"PHASE2":3090,"PHASE3":3096,"PHASE4":3098,"NA":3100},{"trials":3087,"activeCount":100},[],{"trials":3089,"activeCount":100},[],{"trials":3091,"activeCount":100},[3092],{"nctId":3050,"briefTitle":3051,"status":785,"phases":3093,"primaryCompletion":3053,"completion":3053,"start":3054,"enrollment":996,"conditions":3094,"interventions":3095},[89],[3056],[3041,3058,3059],{"trials":3097,"activeCount":100},[],{"trials":3099,"activeCount":100},[],{"trials":3101,"activeCount":100},[],{"intervention":3103,"totalTrials":96,"cells":3104},"Administration of an IV glucose-injection",{"EARLY_PHASE1":3105,"PHASE1":3107,"PHASE2":3109,"PHASE3":3118,"PHASE4":3120,"NA":3122},{"trials":3106,"activeCount":100},[],{"trials":3108,"activeCount":100},[],{"trials":3110,"activeCount":100},[3111],{"nctId":3112,"briefTitle":3113,"status":1044,"phases":3114,"enrollment":100,"conditions":3115,"interventions":3117},"NCT00426114","Acute Haemodynamic Impact of an IV Glucose-injection",[89],[3116],"Peritoneal Dialysis",[3103],{"trials":3119,"activeCount":100},[],{"trials":3121,"activeCount":100},[],{"trials":3123,"activeCount":100},[],{"intervention":3125,"totalTrials":96,"cells":3126},"Administration of intrathecal baclofen",{"EARLY_PHASE1":3127,"PHASE1":3129,"PHASE2":3131,"PHASE3":3142,"PHASE4":3144,"NA":3146},{"trials":3128,"activeCount":100},[],{"trials":3130,"activeCount":100},[],{"trials":3132,"activeCount":100},[3133],{"nctId":3134,"briefTitle":3135,"status":785,"phases":3136,"completion":3137,"start":3138,"enrollment":2051,"conditions":3139,"interventions":3141},"NCT00221611","Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity",[89],"2006-08","2000-01",[3140],"Cerebral Palsy",[3125],{"trials":3143,"activeCount":100},[],{"trials":3145,"activeCount":100},[],{"trials":3147,"activeCount":100},[],{"intervention":3149,"totalTrials":96,"cells":3150},"Oral administration of escitalopram during 8 weeks",{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3166,"PHASE4":3168,"NA":3170},{"trials":3152,"activeCount":100},[],{"trials":3154,"activeCount":100},[],{"trials":3156,"activeCount":100},[3157],{"nctId":3158,"briefTitle":3159,"status":785,"phases":3160,"primaryCompletion":3161,"completion":3161,"start":3162,"enrollment":1245,"conditions":3163,"interventions":3165},"NCT00343070","Functional Neuroimaging in Depression",[89],"2009-10","2007-03",[3164],"Major Depression",[3149],{"trials":3167,"activeCount":100},[],{"trials":3169,"activeCount":100},[],{"trials":3171,"activeCount":100},[],{"intervention":3173,"totalTrials":96,"cells":3174},"TACE-DEB",{"EARLY_PHASE1":3175,"PHASE1":3177,"PHASE2":3179,"PHASE3":3191,"PHASE4":3193,"NA":3195},{"trials":3176,"activeCount":100},[],{"trials":3178,"activeCount":100},[],{"trials":3180,"activeCount":100},[3181],{"nctId":3182,"briefTitle":3183,"status":832,"phases":3184,"primaryCompletion":3185,"completion":3186,"start":1538,"enrollment":1633,"conditions":3187,"interventions":3189},"NCT01381211","Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)",[89],"2018-03","2020-03",[3188],"Hepatocellular Carcinoma",[3173,3190],"90Y-RE",{"trials":3192,"activeCount":100},[],{"trials":3194,"activeCount":100},[],{"trials":3196,"activeCount":100},[],{"intervention":3190,"totalTrials":96,"cells":3198},{"EARLY_PHASE1":3199,"PHASE1":3201,"PHASE2":3203,"PHASE3":3209,"PHASE4":3211,"NA":3213},{"trials":3200,"activeCount":100},[],{"trials":3202,"activeCount":100},[],{"trials":3204,"activeCount":100},[3205],{"nctId":3182,"briefTitle":3183,"status":832,"phases":3206,"primaryCompletion":3185,"completion":3186,"start":1538,"enrollment":1633,"conditions":3207,"interventions":3208},[89],[3188],[3173,3190],{"trials":3210,"activeCount":100},[],{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[],{"intervention":3216,"totalTrials":96,"cells":3217},"Sugammadex 2 mg\u002Fkg",{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3222,"PHASE3":3234,"PHASE4":3236,"NA":3238},{"trials":3219,"activeCount":100},[],{"trials":3221,"activeCount":100},[],{"trials":3223,"activeCount":100},[3224],{"nctId":3225,"briefTitle":3226,"status":785,"phases":3227,"primaryCompletion":3228,"completion":3228,"start":3229,"enrollment":1245,"conditions":3230,"interventions":3232},"NCT01911520","Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients",[89],"2012-06","2011-01",[3231],"Morbidly Obese Patients",[3216,3233],"Sugammadex. 4 mg\u002Fkg",{"trials":3235,"activeCount":100},[],{"trials":3237,"activeCount":100},[],{"trials":3239,"activeCount":100},[],{"intervention":3233,"totalTrials":96,"cells":3241},{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3252,"PHASE4":3254,"NA":3256},{"trials":3243,"activeCount":100},[],{"trials":3245,"activeCount":100},[],{"trials":3247,"activeCount":100},[3248],{"nctId":3225,"briefTitle":3226,"status":785,"phases":3249,"primaryCompletion":3228,"completion":3228,"start":3229,"enrollment":1245,"conditions":3250,"interventions":3251},[89],[3231],[3216,3233],{"trials":3253,"activeCount":100},[],{"trials":3255,"activeCount":100},[],{"trials":3257,"activeCount":100},[],{"intervention":3259,"totalTrials":96,"cells":3260},"perioperative chemotherapy plus bevacizumab",{"EARLY_PHASE1":3261,"PHASE1":3263,"PHASE2":3265,"PHASE3":3277,"PHASE4":3279,"NA":3281},{"trials":3262,"activeCount":100},[],{"trials":3264,"activeCount":100},[],{"trials":3266,"activeCount":100},[3267],{"nctId":3268,"briefTitle":3269,"status":785,"phases":3270,"primaryCompletion":3271,"completion":3271,"start":3272,"enrollment":116,"conditions":3273,"interventions":3275},"NCT02399410","Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis",[89],"2023-11-09","2015-11-04",[3274],"Colorectal Neoplasms",[3259,3276],"Intraperitoneal Oxaliplatin",{"trials":3278,"activeCount":100},[],{"trials":3280,"activeCount":100},[],{"trials":3282,"activeCount":100},[],{"intervention":3276,"totalTrials":96,"cells":3284},{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3295,"PHASE4":3297,"NA":3299},{"trials":3286,"activeCount":100},[],{"trials":3288,"activeCount":100},[],{"trials":3290,"activeCount":100},[3291],{"nctId":3268,"briefTitle":3269,"status":785,"phases":3292,"primaryCompletion":3271,"completion":3271,"start":3272,"enrollment":116,"conditions":3293,"interventions":3294},[89],[3274],[3259,3276],{"trials":3296,"activeCount":100},[],{"trials":3298,"activeCount":100},[],{"trials":3300,"activeCount":100},[],{"intervention":3302,"totalTrials":96,"cells":3303},"Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis",{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3308,"PHASE3":3318,"PHASE4":3320,"NA":3322},{"trials":3305,"activeCount":100},[],{"trials":3307,"activeCount":100},[],{"trials":3309,"activeCount":100},[3310],{"nctId":3311,"briefTitle":3312,"status":785,"phases":3313,"primaryCompletion":1780,"completion":3314,"start":2982,"enrollment":675,"conditions":3315,"interventions":3317},"NCT00323648","Does it Make Sense to Give Postoperative Antibiotics to Patients With an Uncomplicated Acute Cholecystitis",[89],"2013-08",[3316],"Uncomplicated Acute Cholecystitis",[3302],{"trials":3319,"activeCount":100},[],{"trials":3321,"activeCount":100},[],{"trials":3323,"activeCount":100},[],{"intervention":3325,"totalTrials":96,"cells":3326},"Giving DHA-rich supplement",{"EARLY_PHASE1":3327,"PHASE1":3329,"PHASE2":3331,"PHASE3":3342,"PHASE4":3344,"NA":3346},{"trials":3328,"activeCount":100},[],{"trials":3330,"activeCount":100},[],{"trials":3332,"activeCount":100},[3333],{"nctId":3334,"briefTitle":3335,"status":785,"phases":3336,"primaryCompletion":3337,"completion":3337,"start":3338,"enrollment":3339,"conditions":3340,"interventions":3341},"NCT00221546","Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis",[89],"2008-09","2007-09",17,[1158],[3325],{"trials":3343,"activeCount":100},[],{"trials":3345,"activeCount":100},[],{"trials":3347,"activeCount":100},[],{"intervention":3349,"totalTrials":96,"cells":3350},"Botulin toxin",{"EARLY_PHASE1":3351,"PHASE1":3353,"PHASE2":3355,"PHASE3":3368,"PHASE4":3370,"NA":3372},{"trials":3352,"activeCount":100},[],{"trials":3354,"activeCount":100},[],{"trials":3356,"activeCount":100},[3357],{"nctId":3358,"briefTitle":3359,"status":785,"phases":3360,"primaryCompletion":3361,"completion":3362,"start":3363,"enrollment":790,"conditions":3364,"interventions":3366},"NCT01747161","Infiltration of the Vestibulum Vaginae With Botulin Toxin in Patients With Localized Provoked Vulvodynia",[89],"2014-11-13","2018-06-19","2013-12-17",[3365],"Localized Provoked Vulvodynia",[3349,3367],"physiological water",{"trials":3369,"activeCount":100},[],{"trials":3371,"activeCount":100},[],{"trials":3373,"activeCount":100},[],{"intervention":3367,"totalTrials":96,"cells":3375},{"EARLY_PHASE1":3376,"PHASE1":3378,"PHASE2":3380,"PHASE3":3386,"PHASE4":3388,"NA":3390},{"trials":3377,"activeCount":100},[],{"trials":3379,"activeCount":100},[],{"trials":3381,"activeCount":100},[3382],{"nctId":3358,"briefTitle":3359,"status":785,"phases":3383,"primaryCompletion":3361,"completion":3362,"start":3363,"enrollment":790,"conditions":3384,"interventions":3385},[89],[3365],[3349,3367],{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[],{"trials":3391,"activeCount":100},[],{"intervention":3393,"totalTrials":96,"cells":3394},"denosumab",{"EARLY_PHASE1":3395,"PHASE1":3397,"PHASE2":3399,"PHASE3":3411,"PHASE4":3413,"NA":3415},{"trials":3396,"activeCount":100},[],{"trials":3398,"activeCount":100},[],{"trials":3400,"activeCount":100},[3401],{"nctId":3402,"briefTitle":3403,"status":785,"phases":3404,"primaryCompletion":3405,"completion":3406,"start":3407,"enrollment":568,"conditions":3408,"interventions":3410},"NCT02771860","RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints",[89],"2019-06-26","2021-04-28","2016-03",[3409],"Hand Osteoarthritis",[3393],{"trials":3412,"activeCount":100},[],{"trials":3414,"activeCount":100},[],{"trials":3416,"activeCount":100},[],{"intervention":3418,"totalTrials":96,"cells":3419},"Methylprednisolone",{"EARLY_PHASE1":3420,"PHASE1":3422,"PHASE2":3424,"PHASE3":3435,"PHASE4":3437,"NA":3439},{"trials":3421,"activeCount":100},[],{"trials":3423,"activeCount":100},[],{"trials":3425,"activeCount":100},[3426],{"nctId":3427,"briefTitle":3428,"status":785,"phases":3429,"primaryCompletion":3430,"completion":3430,"start":3431,"enrollment":2051,"conditions":3432,"interventions":3434},"NCT00879931","Influence of Corticoids on Renal Function in Cardiac Surgery",[89],"2015-07","2013-01",[3433],"Elective Cardiac Surgery",[3418],{"trials":3436,"activeCount":100},[],{"trials":3438,"activeCount":100},[],{"trials":3440,"activeCount":100},[],{"intervention":3442,"totalTrials":96,"cells":3443},"Lanreotide",{"EARLY_PHASE1":3444,"PHASE1":3446,"PHASE2":3448,"PHASE3":3457,"PHASE4":3459,"NA":3461},{"trials":3445,"activeCount":100},[],{"trials":3447,"activeCount":100},[],{"trials":3449,"activeCount":100},[3450],{"nctId":3451,"briefTitle":3452,"status":785,"phases":3453,"primaryCompletion":798,"completion":798,"start":3161,"enrollment":1245,"conditions":3454,"interventions":3456},"NCT01076803","Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients",[89],[3455],"Malignant Intestinal Obstruction",[3442],{"trials":3458,"activeCount":100},[],{"trials":3460,"activeCount":100},[],{"trials":3462,"activeCount":100},[],{"intervention":3464,"totalTrials":96,"cells":3465},"Aromatase inhibition",{"EARLY_PHASE1":3466,"PHASE1":3468,"PHASE2":3470,"PHASE3":3480,"PHASE4":3482,"NA":3484},{"trials":3467,"activeCount":100},[],{"trials":3469,"activeCount":100},[],{"trials":3471,"activeCount":100},[3472],{"nctId":3473,"briefTitle":3474,"status":785,"phases":3475,"primaryCompletion":1242,"completion":3476,"start":1981,"enrollment":9,"conditions":3477,"interventions":3478},"NCT00740194","Reciprocal Influence of Sex Steroid Environment and Adipocyte Function in Men",[88,89],"2010-08",[34],[3464,3479],"Estradiol",{"trials":3481,"activeCount":100},[],{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[],{"intervention":3479,"totalTrials":96,"cells":3487},{"EARLY_PHASE1":3488,"PHASE1":3490,"PHASE2":3492,"PHASE3":3498,"PHASE4":3500,"NA":3502},{"trials":3489,"activeCount":100},[],{"trials":3491,"activeCount":100},[],{"trials":3493,"activeCount":100},[3494],{"nctId":3473,"briefTitle":3474,"status":785,"phases":3495,"primaryCompletion":1242,"completion":3476,"start":1981,"enrollment":9,"conditions":3496,"interventions":3497},[88,89],[34],[3464,3479],{"trials":3499,"activeCount":100},[],{"trials":3501,"activeCount":100},[],{"trials":3503,"activeCount":100},[],{"intervention":3505,"totalTrials":96,"cells":3506},"Hyperthermic intraoperative Peritoneal Chemoperfusion",{"EARLY_PHASE1":3507,"PHASE1":3509,"PHASE2":3511,"PHASE3":3521,"PHASE4":3523,"NA":3525},{"trials":3508,"activeCount":100},[],{"trials":3510,"activeCount":100},[],{"trials":3512,"activeCount":100},[3513],{"nctId":3514,"briefTitle":3515,"status":785,"phases":3516,"primaryCompletion":3517,"completion":3517,"start":3518,"enrollment":588,"conditions":3519,"interventions":3520},"NCT01575730","Cytoreduction Followed by Normothermic Versus Hyperthermic Intraperitoneal Intraoperative Chemoperfusion (HIPEC): a Study in Peritoneal Carcinomatosis",[89],"2013-03-18","2012-05-21",[590],[3505],{"trials":3522,"activeCount":100},[],{"trials":3524,"activeCount":100},[],{"trials":3526,"activeCount":100},[],{"intervention":3528,"totalTrials":96,"cells":3529},"Administration of high dose simplified folfiri",{"EARLY_PHASE1":3530,"PHASE1":3532,"PHASE2":3534,"PHASE3":3546,"PHASE4":3548,"NA":3550},{"trials":3531,"activeCount":100},[],{"trials":3533,"activeCount":100},[],{"trials":3535,"activeCount":100},[3536],{"nctId":3537,"briefTitle":3538,"status":785,"phases":3539,"completion":3540,"start":3541,"enrollment":3542,"conditions":3543,"interventions":3545},"NCT00286000","High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study",[89],"2005-12","2004-06",106,[3544],"Advanced Colorectal Cancer",[3528],{"trials":3547,"activeCount":100},[],{"trials":3549,"activeCount":100},[],{"trials":3551,"activeCount":100},[],{"intervention":3553,"totalTrials":96,"cells":3554},"Administration of an ACE-inhibitor or not",{"EARLY_PHASE1":3555,"PHASE1":3557,"PHASE2":3559,"PHASE3":3569,"PHASE4":3571,"NA":3573},{"trials":3556,"activeCount":100},[],{"trials":3558,"activeCount":100},[],{"trials":3560,"activeCount":100},[3561],{"nctId":3562,"briefTitle":3563,"status":785,"phases":3564,"completion":3162,"start":3565,"enrollment":1245,"conditions":3566,"interventions":3568},"NCT00263406","Pathophysiological Mechanisms of Hepatopulmonary Influence in the Fontan Circulation",[89],"2002-12",[3567],"Children With a Univentricular Heart Undergoing Surgery for Creation of a Fontan Circulation",[3553],{"trials":3570,"activeCount":100},[],{"trials":3572,"activeCount":100},[],{"trials":3574,"activeCount":100},[],{"intervention":3576,"totalTrials":96,"cells":3577},"Rituximab",{"EARLY_PHASE1":3578,"PHASE1":3580,"PHASE2":3582,"PHASE3":3592,"PHASE4":3594,"NA":3596},{"trials":3579,"activeCount":100},[],{"trials":3581,"activeCount":100},[],{"trials":3583,"activeCount":100},[3584],{"nctId":3585,"briefTitle":3586,"status":785,"phases":3587,"primaryCompletion":3588,"completion":3588,"start":1938,"enrollment":770,"conditions":3589,"interventions":3591},"NCT00936546","A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy",[89],"2015-06-03",[3590],"Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)",[3576],{"trials":3593,"activeCount":100},[],{"trials":3595,"activeCount":100},[],{"trials":3597,"activeCount":100},[],{"intervention":3599,"totalTrials":96,"cells":3600},"Zilucoplan®",{"EARLY_PHASE1":3601,"PHASE1":3603,"PHASE2":3605,"PHASE3":3617,"PHASE4":3619,"NA":3621},{"trials":3602,"activeCount":100},[],{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[3607],{"nctId":3608,"briefTitle":3609,"status":785,"phases":3610,"primaryCompletion":3611,"completion":3612,"start":3613,"enrollment":3614,"conditions":3615,"interventions":3616},"NCT04382755","Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure",[89],"2020-12-29","2021-04-09","2020-05-22",81,[1403],[3599],{"trials":3618,"activeCount":100},[],{"trials":3620,"activeCount":100},[],{"trials":3622,"activeCount":100},[],{"intervention":3624,"totalTrials":96,"cells":3625},"Adalimumab",{"EARLY_PHASE1":3626,"PHASE1":3628,"PHASE2":3630,"PHASE3":3640,"PHASE4":3642,"NA":3644},{"trials":3627,"activeCount":100},[],{"trials":3629,"activeCount":100},[],{"trials":3631,"activeCount":100},[3632],{"nctId":3633,"briefTitle":3634,"status":785,"phases":3635,"primaryCompletion":1243,"completion":3636,"start":2982,"enrollment":116,"conditions":3637,"interventions":3639},"NCT00296894","Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints",[89],"2009-02",[3638],"Erosive Osteo-Arthritis",[3624],{"trials":3641,"activeCount":100},[],{"trials":3643,"activeCount":100},[],{"trials":3645,"activeCount":100},[],{"intervention":3647,"totalTrials":96,"cells":3648},"IPEC with Cisplatin",{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3653,"PHASE3":3668,"PHASE4":3670,"NA":3672},{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":100},[],{"trials":3654,"activeCount":100},[3655],{"nctId":3656,"briefTitle":3657,"status":785,"phases":3658,"primaryCompletion":3659,"completion":3660,"start":3407,"enrollment":3661,"conditions":3662,"interventions":3665},"NCT02567253","Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer",[89],"2020-12-31","2021-08-25",56,[3663,3664],"Ovarian Cancer","Primary Peritoneal Cancer",[3647,3647,3666,3667],"Hypertherm IntraPEritoneal Chemotherapy with Cisplatin","HIPEC with Cisplatin",{"trials":3669,"activeCount":100},[],{"trials":3671,"activeCount":100},[],{"trials":3673,"activeCount":100},[],{"intervention":3666,"totalTrials":96,"cells":3675},{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3680,"PHASE3":3686,"PHASE4":3688,"NA":3690},{"trials":3677,"activeCount":100},[],{"trials":3679,"activeCount":100},[],{"trials":3681,"activeCount":100},[3682],{"nctId":3656,"briefTitle":3657,"status":785,"phases":3683,"primaryCompletion":3659,"completion":3660,"start":3407,"enrollment":3661,"conditions":3684,"interventions":3685},[89],[3663,3664],[3647,3647,3666,3667],{"trials":3687,"activeCount":100},[],{"trials":3689,"activeCount":100},[],{"trials":3691,"activeCount":100},[],{"intervention":3667,"totalTrials":96,"cells":3693},{"EARLY_PHASE1":3694,"PHASE1":3696,"PHASE2":3698,"PHASE3":3704,"PHASE4":3706,"NA":3708},{"trials":3695,"activeCount":100},[],{"trials":3697,"activeCount":100},[],{"trials":3699,"activeCount":100},[3700],{"nctId":3656,"briefTitle":3657,"status":785,"phases":3701,"primaryCompletion":3659,"completion":3660,"start":3407,"enrollment":3661,"conditions":3702,"interventions":3703},[89],[3663,3664],[3647,3647,3666,3667],{"trials":3705,"activeCount":100},[],{"trials":3707,"activeCount":100},[],{"trials":3709,"activeCount":100},[],{"intervention":3711,"totalTrials":96,"cells":3712},"Association of gemcitabine, oxaliplatin and radiotherapy",{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3717,"PHASE3":3729,"PHASE4":3731,"NA":3733},{"trials":3714,"activeCount":100},[],{"trials":3716,"activeCount":100},[],{"trials":3718,"activeCount":100},[3719],{"nctId":3720,"briefTitle":3721,"status":785,"phases":3722,"primaryCompletion":3723,"completion":3724,"start":3725,"enrollment":809,"conditions":3726,"interventions":3728},"NCT00286013","Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma",[89],"2006-05-31","2008-07-22","2004-05-01",[3727],"Locally Advanced and Unresectable, But Non-metastatic Pancreatic Adenocarcinoma or Cholangiocarcinoma",[3711],{"trials":3730,"activeCount":100},[],{"trials":3732,"activeCount":100},[],{"trials":3734,"activeCount":100},[],{"intervention":3736,"totalTrials":96,"cells":3737},"IV and enteral administration of moxifloxacin",{"EARLY_PHASE1":3738,"PHASE1":3740,"PHASE2":3742,"PHASE3":3753,"PHASE4":3755,"NA":3757},{"trials":3739,"activeCount":100},[],{"trials":3741,"activeCount":100},[],{"trials":3743,"activeCount":100},[3744],{"nctId":3745,"briefTitle":3746,"status":785,"phases":3747,"primaryCompletion":3748,"completion":3748,"start":3749,"enrollment":1782,"conditions":3750,"interventions":3752},"NCT00458900","Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients",[89],"2012-09","2007-07",[3751],"Pneumonia",[3736],{"trials":3754,"activeCount":100},[],{"trials":3756,"activeCount":100},[],{"trials":3758,"activeCount":100},[],{"intervention":3760,"totalTrials":96,"cells":3761},"Administration of oral methylprednisolone",{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3766,"PHASE3":3777,"PHASE4":3779,"NA":3781},{"trials":3763,"activeCount":100},[],{"trials":3765,"activeCount":100},[],{"trials":3767,"activeCount":100},[3768],{"nctId":3769,"briefTitle":3770,"status":785,"phases":3771,"completion":3772,"start":3773,"enrollment":930,"conditions":3774,"interventions":3776},"NCT00480298","Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis",[89],"2006-07","2002-11",[3775],"Nasal Polyposis",[3760],{"trials":3778,"activeCount":100},[],{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[],{"intervention":2486,"totalTrials":96,"cells":3784},{"EARLY_PHASE1":3785,"PHASE1":3787,"PHASE2":3789,"PHASE3":3795,"PHASE4":3797,"NA":3799},{"trials":3786,"activeCount":100},[],{"trials":3788,"activeCount":100},[],{"trials":3790,"activeCount":100},[3791],{"nctId":2474,"briefTitle":2475,"status":785,"phases":3792,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":2479,"conditions":3793,"interventions":3794},[89],[2481,2482,2483],[2485,2486,2487,2488,2489],{"trials":3796,"activeCount":100},[],{"trials":3798,"activeCount":100},[],{"trials":3800,"activeCount":100},[],{"intervention":2488,"totalTrials":96,"cells":3802},{"EARLY_PHASE1":3803,"PHASE1":3805,"PHASE2":3807,"PHASE3":3813,"PHASE4":3815,"NA":3817},{"trials":3804,"activeCount":100},[],{"trials":3806,"activeCount":100},[],{"trials":3808,"activeCount":100},[3809],{"nctId":2474,"briefTitle":2475,"status":785,"phases":3810,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":2479,"conditions":3811,"interventions":3812},[89],[2481,2482,2483],[2485,2486,2487,2488,2489],{"trials":3814,"activeCount":100},[],{"trials":3816,"activeCount":100},[],{"trials":3818,"activeCount":100},[],{"intervention":3820,"totalTrials":96,"cells":3821},"to implement an insulin protocol with target blood glucose levels between 81-110 mg\u002FdL.",{"EARLY_PHASE1":3822,"PHASE1":3824,"PHASE2":3826,"PHASE3":3836,"PHASE4":3838,"NA":3840},{"trials":3823,"activeCount":100},[],{"trials":3825,"activeCount":100},[],{"trials":3827,"activeCount":100},[3828],{"nctId":3829,"briefTitle":3830,"status":785,"phases":3831,"completion":3565,"start":3832,"enrollment":996,"conditions":3833,"interventions":3835},"NCT00288743","Adherence, Efficacy and Safety of an Insulin Protocol in the Critically Ill: A Prospective Observational Study",[89],"2002-09",[3834],"Critically Ill Patients",[3820],{"trials":3837,"activeCount":100},[],{"trials":3839,"activeCount":100},[],{"trials":3841,"activeCount":100},[],{"intervention":3843,"totalTrials":96,"cells":3844},"doxycycline 100 mg",{"EARLY_PHASE1":3845,"PHASE1":3847,"PHASE2":3849,"PHASE3":3861,"PHASE4":3863,"NA":3865},{"trials":3846,"activeCount":100},[],{"trials":3848,"activeCount":100},[],{"trials":3850,"activeCount":100},[3851],{"nctId":3852,"briefTitle":3853,"status":785,"phases":3854,"primaryCompletion":3855,"completion":957,"start":3856,"enrollment":958,"conditions":3857,"interventions":3860},"NCT01198912","Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial",[89],"2016-09-06","2011-11-22",[3858,3859],"Chronic Rhinosinusitis","Nasal Polyps",[3843],{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[],{"intervention":3868,"totalTrials":96,"cells":3869},"Camostat",{"EARLY_PHASE1":3870,"PHASE1":3872,"PHASE2":3874,"PHASE3":3886,"PHASE4":3888,"NA":3890},{"trials":3871,"activeCount":100},[],{"trials":3873,"activeCount":100},[],{"trials":3875,"activeCount":100},[3876],{"nctId":3877,"briefTitle":3878,"status":832,"phases":3879,"primaryCompletion":3880,"completion":3880,"start":3881,"enrollment":3882,"conditions":3883,"interventions":3885},"NCT04625114","The Potential of Camostat in COVID-19",[89],"2022-07-12","2020-11-04",108,[3884],"Covid19",[3868,3868],{"trials":3887,"activeCount":100},[],{"trials":3889,"activeCount":100},[],{"trials":3891,"activeCount":100},[],{"intervention":3893,"totalTrials":96,"cells":3894},"Fixed sevoflurane dose 1",{"EARLY_PHASE1":3895,"PHASE1":3897,"PHASE2":3899,"PHASE3":3921,"PHASE4":3923,"NA":3925},{"trials":3896,"activeCount":100},[],{"trials":3898,"activeCount":100},[],{"trials":3900,"activeCount":100},[3901],{"nctId":3902,"briefTitle":3903,"status":785,"phases":3904,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":3907,"interventions":3909},"NCT00522587","Sevoflurane-Remifentanil Interaction: Multiple Response Surfaces, Validation of Calibration Stimuli, Validation of the Intraoperative Isobole Concept and Investigating Remifentanil Induced Opioid Tolerance",[89],"2009-07","2008-04",[3908],"Anesthesia",[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],"Fixed sevoflurane dose 2","Fixed sevoflurane dose 3","Fixed sevoflurane dose 4","Fixed sevoflurane dose 5","Fixed sevoflurane dose 6","Fixed remifentanil dose 1","Fixed remifentanil dose 2","Fixed remifentanil dose 3","Fixed remifentanil dose 4","Fixed remifentanil dose 5","Fixed remifentanil dose 6",{"trials":3922,"activeCount":100},[],{"trials":3924,"activeCount":100},[],{"trials":3926,"activeCount":100},[],{"intervention":3910,"totalTrials":96,"cells":3928},{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3933,"PHASE3":3939,"PHASE4":3941,"NA":3943},{"trials":3930,"activeCount":100},[],{"trials":3932,"activeCount":100},[],{"trials":3934,"activeCount":100},[3935],{"nctId":3902,"briefTitle":3903,"status":785,"phases":3936,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":3937,"interventions":3938},[89],[3908],[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],{"trials":3940,"activeCount":100},[],{"trials":3942,"activeCount":100},[],{"trials":3944,"activeCount":100},[],{"intervention":3911,"totalTrials":96,"cells":3946},{"EARLY_PHASE1":3947,"PHASE1":3949,"PHASE2":3951,"PHASE3":3957,"PHASE4":3959,"NA":3961},{"trials":3948,"activeCount":100},[],{"trials":3950,"activeCount":100},[],{"trials":3952,"activeCount":100},[3953],{"nctId":3902,"briefTitle":3903,"status":785,"phases":3954,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":3955,"interventions":3956},[89],[3908],[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],{"trials":3958,"activeCount":100},[],{"trials":3960,"activeCount":100},[],{"trials":3962,"activeCount":100},[],{"intervention":3912,"totalTrials":96,"cells":3964},{"EARLY_PHASE1":3965,"PHASE1":3967,"PHASE2":3969,"PHASE3":3975,"PHASE4":3977,"NA":3979},{"trials":3966,"activeCount":100},[],{"trials":3968,"activeCount":100},[],{"trials":3970,"activeCount":100},[3971],{"nctId":3902,"briefTitle":3903,"status":785,"phases":3972,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":3973,"interventions":3974},[89],[3908],[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],{"trials":3976,"activeCount":100},[],{"trials":3978,"activeCount":100},[],{"trials":3980,"activeCount":100},[],{"intervention":3913,"totalTrials":96,"cells":3982},{"EARLY_PHASE1":3983,"PHASE1":3985,"PHASE2":3987,"PHASE3":3993,"PHASE4":3995,"NA":3997},{"trials":3984,"activeCount":100},[],{"trials":3986,"activeCount":100},[],{"trials":3988,"activeCount":100},[3989],{"nctId":3902,"briefTitle":3903,"status":785,"phases":3990,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":3991,"interventions":3992},[89],[3908],[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],{"trials":3994,"activeCount":100},[],{"trials":3996,"activeCount":100},[],{"trials":3998,"activeCount":100},[],{"intervention":3914,"totalTrials":96,"cells":4000},{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4005,"PHASE3":4011,"PHASE4":4013,"NA":4015},{"trials":4002,"activeCount":100},[],{"trials":4004,"activeCount":100},[],{"trials":4006,"activeCount":100},[4007],{"nctId":3902,"briefTitle":3903,"status":785,"phases":4008,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":4009,"interventions":4010},[89],[3908],[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],{"trials":4012,"activeCount":100},[],{"trials":4014,"activeCount":100},[],{"trials":4016,"activeCount":100},[],{"intervention":3915,"totalTrials":96,"cells":4018},{"EARLY_PHASE1":4019,"PHASE1":4021,"PHASE2":4023,"PHASE3":4029,"PHASE4":4031,"NA":4033},{"trials":4020,"activeCount":100},[],{"trials":4022,"activeCount":100},[],{"trials":4024,"activeCount":100},[4025],{"nctId":3902,"briefTitle":3903,"status":785,"phases":4026,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":4027,"interventions":4028},[89],[3908],[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],{"trials":4030,"activeCount":100},[],{"trials":4032,"activeCount":100},[],{"trials":4034,"activeCount":100},[],{"intervention":3916,"totalTrials":96,"cells":4036},{"EARLY_PHASE1":4037,"PHASE1":4039,"PHASE2":4041,"PHASE3":4047,"PHASE4":4049,"NA":4051},{"trials":4038,"activeCount":100},[],{"trials":4040,"activeCount":100},[],{"trials":4042,"activeCount":100},[4043],{"nctId":3902,"briefTitle":3903,"status":785,"phases":4044,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":4045,"interventions":4046},[89],[3908],[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],{"trials":4048,"activeCount":100},[],{"trials":4050,"activeCount":100},[],{"trials":4052,"activeCount":100},[],{"intervention":3917,"totalTrials":96,"cells":4054},{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4059,"PHASE3":4065,"PHASE4":4067,"NA":4069},{"trials":4056,"activeCount":100},[],{"trials":4058,"activeCount":100},[],{"trials":4060,"activeCount":100},[4061],{"nctId":3902,"briefTitle":3903,"status":785,"phases":4062,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":4063,"interventions":4064},[89],[3908],[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],{"trials":4066,"activeCount":100},[],{"trials":4068,"activeCount":100},[],{"trials":4070,"activeCount":100},[],{"intervention":3918,"totalTrials":96,"cells":4072},{"EARLY_PHASE1":4073,"PHASE1":4075,"PHASE2":4077,"PHASE3":4083,"PHASE4":4085,"NA":4087},{"trials":4074,"activeCount":100},[],{"trials":4076,"activeCount":100},[],{"trials":4078,"activeCount":100},[4079],{"nctId":3902,"briefTitle":3903,"status":785,"phases":4080,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":4081,"interventions":4082},[89],[3908],[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],{"trials":4084,"activeCount":100},[],{"trials":4086,"activeCount":100},[],{"trials":4088,"activeCount":100},[],{"intervention":3919,"totalTrials":96,"cells":4090},{"EARLY_PHASE1":4091,"PHASE1":4093,"PHASE2":4095,"PHASE3":4101,"PHASE4":4103,"NA":4105},{"trials":4092,"activeCount":100},[],{"trials":4094,"activeCount":100},[],{"trials":4096,"activeCount":100},[4097],{"nctId":3902,"briefTitle":3903,"status":785,"phases":4098,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":4099,"interventions":4100},[89],[3908],[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],{"trials":4102,"activeCount":100},[],{"trials":4104,"activeCount":100},[],{"trials":4106,"activeCount":100},[],{"intervention":3920,"totalTrials":96,"cells":4108},{"EARLY_PHASE1":4109,"PHASE1":4111,"PHASE2":4113,"PHASE3":4119,"PHASE4":4121,"NA":4123},{"trials":4110,"activeCount":100},[],{"trials":4112,"activeCount":100},[],{"trials":4114,"activeCount":100},[4115],{"nctId":3902,"briefTitle":3903,"status":785,"phases":4116,"primaryCompletion":3905,"completion":2731,"start":3906,"enrollment":1245,"conditions":4117,"interventions":4118},[89],[3908],[3893,3910,3911,3912,3913,3914,3915,3916,3917,3918,3919,3920],{"trials":4120,"activeCount":100},[],{"trials":4122,"activeCount":100},[],{"trials":4124,"activeCount":100},[],{"intervention":4126,"totalTrials":96,"cells":4127},"Administration of zinkgluconaat or placebo",{"EARLY_PHASE1":4128,"PHASE1":4130,"PHASE2":4132,"PHASE3":4143,"PHASE4":4145,"NA":4147},{"trials":4129,"activeCount":100},[],{"trials":4131,"activeCount":100},[],{"trials":4133,"activeCount":100},[4134],{"nctId":4135,"briefTitle":4136,"status":785,"phases":4137,"completion":4138,"start":4139,"enrollment":763,"conditions":4140,"interventions":4142},"NCT00228332","A Trial Investigating the Effect of a Treatment With Zinkgluconaat for Verrucae Vulgares",[89],"2006-03","2004-04",[4141],"Verrucae Vulgares",[4126],{"trials":4144,"activeCount":100},[],{"trials":4146,"activeCount":100},[],{"trials":4148,"activeCount":100},[],{"intervention":4150,"totalTrials":96,"cells":4151},"Alendronate Effervescent Oral",{"EARLY_PHASE1":4152,"PHASE1":4154,"PHASE2":4156,"PHASE3":4167,"PHASE4":4169,"NA":4171},{"trials":4153,"activeCount":100},[],{"trials":4155,"activeCount":100},[],{"trials":4157,"activeCount":100},[4158],{"nctId":4159,"briefTitle":4160,"status":785,"phases":4161,"primaryCompletion":4162,"completion":4162,"start":4163,"enrollment":996,"conditions":4164,"interventions":4166},"NCT04403698","The Use of Steovess\u002FBinosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover",[89],"2022-03-09","2019-11-13",[4165],"Erosive Osteoarthritis",[4150],{"trials":4168,"activeCount":100},[],{"trials":4170,"activeCount":100},[],{"trials":4172,"activeCount":100},[],{"intervention":4174,"totalTrials":96,"cells":4175},"Darolutamide",{"EARLY_PHASE1":4176,"PHASE1":4178,"PHASE2":4180,"PHASE3":4193,"PHASE4":4195,"NA":4197},{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[],{"trials":4181,"activeCount":100},[4182],{"nctId":4183,"briefTitle":4184,"status":1888,"phases":4185,"primaryCompletion":4186,"completion":4186,"start":4187,"enrollment":4188,"conditions":4189,"interventions":4192},"NCT04641078","Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer",[89],"2026-02-12","2021-02-12",124,[15,4190,521,522,4191],"Prostate Cancer Recurrent","Oligometastasis",[4174],{"trials":4194,"activeCount":100},[],{"trials":4196,"activeCount":100},[],{"trials":4198,"activeCount":100},[],{"intervention":4200,"totalTrials":96,"cells":4201},"Nivolumab or Pembrolizumab or Atezolizumab",{"EARLY_PHASE1":4202,"PHASE1":4204,"PHASE2":4206,"PHASE3":4223,"PHASE4":4225,"NA":4227},{"trials":4203,"activeCount":100},[],{"trials":4205,"activeCount":100},[],{"trials":4207,"activeCount":100},[4208],{"nctId":4209,"briefTitle":4210,"status":785,"phases":4211,"primaryCompletion":4212,"completion":4213,"start":4214,"enrollment":4215,"conditions":4216,"interventions":4222},"NCT03511391","CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors",[89],"2022-02-01","2024-01-23","2018-03-09",99,[4217,4218,4219,4220,4221],"Urothelial Carcinoma","Melanoma","Renal Cell Carcinoma","Non-small Cell Lung Cancer","Head and Neck Cancer",[4200],{"trials":4224,"activeCount":100},[],{"trials":4226,"activeCount":100},[],{"trials":4228,"activeCount":100},[],{"intervention":4230,"totalTrials":96,"cells":4231},"Cetuximab",{"EARLY_PHASE1":4232,"PHASE1":4234,"PHASE2":4236,"PHASE3":4246,"PHASE4":4248,"NA":4250},{"trials":4233,"activeCount":100},[],{"trials":4235,"activeCount":100},[],{"trials":4237,"activeCount":100},[4238],{"nctId":4239,"briefTitle":4240,"status":785,"phases":4241,"primaryCompletion":4242,"completion":4242,"start":3161,"enrollment":1707,"conditions":4243,"interventions":4245},"NCT00996567","A Study of Cetuximab Combined With Cisplatin or Carboplatin\u002FPemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.",[89],"2015-09",[4244],"Cancer",[4230],{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"trials":4251,"activeCount":100},[],{"intervention":4253,"totalTrials":96,"cells":4254},"Omalizumab",{"EARLY_PHASE1":4255,"PHASE1":4257,"PHASE2":4259,"PHASE3":4270,"PHASE4":4272,"NA":4274},{"trials":4256,"activeCount":100},[],{"trials":4258,"activeCount":100},[],{"trials":4260,"activeCount":100},[4261],{"nctId":4262,"briefTitle":4263,"status":785,"phases":4264,"primaryCompletion":4265,"completion":808,"start":4266,"enrollment":4267,"conditions":4268,"interventions":4269},"NCT01393340","Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma",[89],"2008-10","2006-12",23,[3775,1542],[4253],{"trials":4271,"activeCount":100},[],{"trials":4273,"activeCount":100},[],{"trials":4275,"activeCount":100},[],{"intervention":4277,"totalTrials":96,"cells":4278},"Administration of omeprazole suspension",{"EARLY_PHASE1":4279,"PHASE1":4281,"PHASE2":4283,"PHASE3":4295,"PHASE4":4297,"NA":4299},{"trials":4280,"activeCount":100},[],{"trials":4282,"activeCount":100},[],{"trials":4284,"activeCount":100},[4285],{"nctId":4286,"briefTitle":4287,"status":785,"phases":4288,"primaryCompletion":4289,"completion":4289,"start":4290,"enrollment":1073,"conditions":4291,"interventions":4293},"NCT00426595","Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation",[89],"2007-11","2007-04",[4292],"Gastreoesophageal Reflux Disease",[4277,4294],"omeprazole administered as a multi-unit-pellet system",{"trials":4296,"activeCount":100},[],{"trials":4298,"activeCount":100},[],{"trials":4300,"activeCount":100},[],{"intervention":4294,"totalTrials":96,"cells":4302},{"EARLY_PHASE1":4303,"PHASE1":4305,"PHASE2":4307,"PHASE3":4313,"PHASE4":4315,"NA":4317},{"trials":4304,"activeCount":100},[],{"trials":4306,"activeCount":100},[],{"trials":4308,"activeCount":100},[4309],{"nctId":4286,"briefTitle":4287,"status":785,"phases":4310,"primaryCompletion":4289,"completion":4289,"start":4290,"enrollment":1073,"conditions":4311,"interventions":4312},[89],[4292],[4277,4294],{"trials":4314,"activeCount":100},[],{"trials":4316,"activeCount":100},[],{"trials":4318,"activeCount":100},[],{"intervention":4320,"totalTrials":868,"cells":4321},"Dendritic cell immunotherapy",{"EARLY_PHASE1":4322,"PHASE1":4324,"PHASE2":4346,"PHASE3":4348,"PHASE4":4350,"NA":4352},{"trials":4323,"activeCount":100},[],{"trials":4325,"activeCount":100},[4326,4337],{"nctId":4327,"briefTitle":4328,"status":1888,"phases":4329,"primaryCompletion":4330,"completion":2938,"start":4331,"enrollment":32,"conditions":4332,"interventions":4334},"NCT04082182","MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer",[88],"2021-06-07","2019-08-26",[4333],"Non-small Cell Lung Cancer Metastatic",[4320,4335,4336],"Antigen-specific DTH","Control DTH",{"nctId":4338,"briefTitle":4339,"status":785,"phases":4340,"primaryCompletion":4341,"completion":4342,"start":4331,"enrollment":4343,"conditions":4344,"interventions":4345},"NCT04078269","MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer",[88],"2024-02-01","2025-03-03",6,[4220],[4320,4335,4336],{"trials":4347,"activeCount":100},[],{"trials":4349,"activeCount":100},[],{"trials":4351,"activeCount":100},[],{"trials":4353,"activeCount":100},[],{"intervention":4335,"totalTrials":868,"cells":4355},{"EARLY_PHASE1":4356,"PHASE1":4358,"PHASE2":4368,"PHASE3":4370,"PHASE4":4372,"NA":4374},{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[4360,4364],{"nctId":4327,"briefTitle":4328,"status":1888,"phases":4361,"primaryCompletion":4330,"completion":2938,"start":4331,"enrollment":32,"conditions":4362,"interventions":4363},[88],[4333],[4320,4335,4336],{"nctId":4338,"briefTitle":4339,"status":785,"phases":4365,"primaryCompletion":4341,"completion":4342,"start":4331,"enrollment":4343,"conditions":4366,"interventions":4367},[88],[4220],[4320,4335,4336],{"trials":4369,"activeCount":100},[],{"trials":4371,"activeCount":100},[],{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[],{"intervention":4336,"totalTrials":868,"cells":4377},{"EARLY_PHASE1":4378,"PHASE1":4380,"PHASE2":4390,"PHASE3":4392,"PHASE4":4394,"NA":4396},{"trials":4379,"activeCount":100},[],{"trials":4381,"activeCount":100},[4382,4386],{"nctId":4327,"briefTitle":4328,"status":1888,"phases":4383,"primaryCompletion":4330,"completion":2938,"start":4331,"enrollment":32,"conditions":4384,"interventions":4385},[88],[4333],[4320,4335,4336],{"nctId":4338,"briefTitle":4339,"status":785,"phases":4387,"primaryCompletion":4341,"completion":4342,"start":4331,"enrollment":4343,"conditions":4388,"interventions":4389},[88],[4220],[4320,4335,4336],{"trials":4391,"activeCount":100},[],{"trials":4393,"activeCount":100},[],{"trials":4395,"activeCount":100},[],{"trials":4397,"activeCount":100},[],{"intervention":4399,"totalTrials":96,"cells":4400},"Ritodrine",{"EARLY_PHASE1":4401,"PHASE1":4403,"PHASE2":4413,"PHASE3":4415,"PHASE4":4417,"NA":4419},{"trials":4402,"activeCount":100},[],{"trials":4404,"activeCount":100},[4405],{"nctId":4406,"briefTitle":4407,"status":785,"phases":4408,"primaryCompletion":1424,"completion":1424,"start":4409,"enrollment":4267,"conditions":4410,"interventions":4411},"NCT00679705","Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself",[88],"2008-05",[34],[4399,4412],"Atosiban",{"trials":4414,"activeCount":100},[],{"trials":4416,"activeCount":100},[],{"trials":4418,"activeCount":100},[],{"trials":4420,"activeCount":100},[],{"intervention":4412,"totalTrials":96,"cells":4422},{"EARLY_PHASE1":4423,"PHASE1":4425,"PHASE2":4431,"PHASE3":4433,"PHASE4":4435,"NA":4437},{"trials":4424,"activeCount":100},[],{"trials":4426,"activeCount":100},[4427],{"nctId":4406,"briefTitle":4407,"status":785,"phases":4428,"primaryCompletion":1424,"completion":1424,"start":4409,"enrollment":4267,"conditions":4429,"interventions":4430},[88],[34],[4399,4412],{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[],{"trials":4436,"activeCount":100},[],{"trials":4438,"activeCount":100},[],{"intervention":4440,"totalTrials":96,"cells":4441},"Artesunate",{"EARLY_PHASE1":4442,"PHASE1":4444,"PHASE2":4454,"PHASE3":4456,"PHASE4":4458,"NA":4460},{"trials":4443,"activeCount":100},[],{"trials":4445,"activeCount":100},[4446],{"nctId":4447,"briefTitle":4448,"status":832,"phases":4449,"primaryCompletion":4450,"completion":4450,"start":4451,"enrollment":868,"conditions":4452,"interventions":4453},"NCT02304289","Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma",[88],"2016-12","2014-11",[3188],[4440],{"trials":4455,"activeCount":100},[],{"trials":4457,"activeCount":100},[],{"trials":4459,"activeCount":100},[],{"trials":4461,"activeCount":100},[],{"intervention":4463,"totalTrials":96,"cells":4464},"a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine",{"EARLY_PHASE1":4465,"PHASE1":4467,"PHASE2":4479,"PHASE3":4481,"PHASE4":4483,"NA":4485},{"trials":4466,"activeCount":100},[],{"trials":4468,"activeCount":100},[4469],{"nctId":4470,"briefTitle":4471,"status":785,"phases":4472,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":696,"conditions":4475,"interventions":4477},"NCT01997632","Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults",[88],"2014-05","2013-11",[4476],"Poliomyelitis",[4463,4478],"a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).",{"trials":4480,"activeCount":100},[],{"trials":4482,"activeCount":100},[],{"trials":4484,"activeCount":100},[],{"trials":4486,"activeCount":100},[],{"intervention":4478,"totalTrials":96,"cells":4488},{"EARLY_PHASE1":4489,"PHASE1":4491,"PHASE2":4497,"PHASE3":4499,"PHASE4":4501,"NA":4503},{"trials":4490,"activeCount":100},[],{"trials":4492,"activeCount":100},[4493],{"nctId":4470,"briefTitle":4471,"status":785,"phases":4494,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":696,"conditions":4495,"interventions":4496},[88],[4476],[4463,4478],{"trials":4498,"activeCount":100},[],{"trials":4500,"activeCount":100},[],{"trials":4502,"activeCount":100},[],{"trials":4504,"activeCount":100},[],{"intervention":4506,"totalTrials":96,"cells":4507},"PIPAC with Abraxane",{"EARLY_PHASE1":4508,"PHASE1":4510,"PHASE2":4530,"PHASE3":4532,"PHASE4":4534,"NA":4536},{"trials":4509,"activeCount":100},[],{"trials":4511,"activeCount":100},[4512],{"nctId":4513,"briefTitle":4514,"status":785,"phases":4515,"primaryCompletion":4516,"completion":4516,"start":4517,"enrollment":9,"conditions":4518,"interventions":4529},"NCT03304210","PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer",[88],"2020-05-06","2017-09-16",[590,4519,4520,4521,4522,4523,4524,4525,4526,4527,4528],"Ovarian Cancer Stage IIIB","Ovarian Cancer Stage IIIC","Ovarian Cancer Stage IV","Breast Cancer Stage IIIB","Breast Cancer Stage IIIc","Breast Cancer Stage IV","Stomach Cancer Stage III","Stomach Cancer Stage IV With Metastases","Pancreas Cancer, Stage III","Pancreas Cancer, Stage IV",[4506],{"trials":4531,"activeCount":100},[],{"trials":4533,"activeCount":100},[],{"trials":4535,"activeCount":100},[],{"trials":4537,"activeCount":100},[],{"intervention":4539,"totalTrials":96,"cells":4540},"Neurontin® (gabapentin) batch A",{"EARLY_PHASE1":4541,"PHASE1":4543,"PHASE2":4557,"PHASE3":4559,"PHASE4":4561,"NA":4563},{"trials":4542,"activeCount":100},[],{"trials":4544,"activeCount":100},[4545],{"nctId":4546,"briefTitle":4547,"status":785,"phases":4548,"primaryCompletion":4474,"completion":4474,"start":4549,"enrollment":4550,"conditions":4551,"interventions":4553},"NCT01821235","Evaluation of Individual Bioequivalence of Gabasandoz® Relative to Neurontin® in Healthy Volunteers",[88],"2013-04",51,[4552],"Epilepsy and Neuropathic Pain",[4539,4554,4555,4556],"Neurontin® (gabapentin) batch B","Gabasandoz® (gabapentin) batch A","Gabasandoz® (gabapentin) batch B",{"trials":4558,"activeCount":100},[],{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[],{"trials":4564,"activeCount":100},[],{"intervention":4554,"totalTrials":96,"cells":4566},{"EARLY_PHASE1":4567,"PHASE1":4569,"PHASE2":4575,"PHASE3":4577,"PHASE4":4579,"NA":4581},{"trials":4568,"activeCount":100},[],{"trials":4570,"activeCount":100},[4571],{"nctId":4546,"briefTitle":4547,"status":785,"phases":4572,"primaryCompletion":4474,"completion":4474,"start":4549,"enrollment":4550,"conditions":4573,"interventions":4574},[88],[4552],[4539,4554,4555,4556],{"trials":4576,"activeCount":100},[],{"trials":4578,"activeCount":100},[],{"trials":4580,"activeCount":100},[],{"trials":4582,"activeCount":100},[],{"intervention":4555,"totalTrials":96,"cells":4584},{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4593,"PHASE3":4595,"PHASE4":4597,"NA":4599},{"trials":4586,"activeCount":100},[],{"trials":4588,"activeCount":100},[4589],{"nctId":4546,"briefTitle":4547,"status":785,"phases":4590,"primaryCompletion":4474,"completion":4474,"start":4549,"enrollment":4550,"conditions":4591,"interventions":4592},[88],[4552],[4539,4554,4555,4556],{"trials":4594,"activeCount":100},[],{"trials":4596,"activeCount":100},[],{"trials":4598,"activeCount":100},[],{"trials":4600,"activeCount":100},[],{"intervention":4556,"totalTrials":96,"cells":4602},{"EARLY_PHASE1":4603,"PHASE1":4605,"PHASE2":4611,"PHASE3":4613,"PHASE4":4615,"NA":4617},{"trials":4604,"activeCount":100},[],{"trials":4606,"activeCount":100},[4607],{"nctId":4546,"briefTitle":4547,"status":785,"phases":4608,"primaryCompletion":4474,"completion":4474,"start":4549,"enrollment":4550,"conditions":4609,"interventions":4610},[88],[4552],[4539,4554,4555,4556],{"trials":4612,"activeCount":100},[],{"trials":4614,"activeCount":100},[],{"trials":4616,"activeCount":100},[],{"trials":4618,"activeCount":100},[],{"intervention":2779,"totalTrials":96,"cells":4620},{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4629,"PHASE3":4631,"PHASE4":4633,"NA":4635},{"trials":4622,"activeCount":100},[],{"trials":4624,"activeCount":100},[4625],{"nctId":2772,"briefTitle":2773,"status":785,"phases":4626,"primaryCompletion":2077,"completion":2775,"start":1154,"enrollment":958,"conditions":4627,"interventions":4628},[88],[2777],[2779,2765],{"trials":4630,"activeCount":100},[],{"trials":4632,"activeCount":100},[],{"trials":4634,"activeCount":100},[],{"trials":4636,"activeCount":100},[],{"intervention":4638,"totalTrials":96,"cells":4639},"Collagenase histiolyticum",{"EARLY_PHASE1":4640,"PHASE1":4655,"PHASE2":4657,"PHASE3":4659,"PHASE4":4661,"NA":4663},{"trials":4641,"activeCount":100},[4642],{"nctId":4643,"briefTitle":4644,"status":832,"phases":4645,"primaryCompletion":4646,"completion":4647,"start":4648,"enrollment":868,"conditions":4649,"interventions":4654},"NCT03898661","Collagenase Clostridium Histolyticum for Refractory Iatrogenic Esophageal Strictures",[87],"2020-06-30","2021-01-01","2019-03-29",[4650,4651,4652,4653],"Stricture","Esophageal Stricture","Anastomotic","Collagenosis",[4638],{"trials":4656,"activeCount":100},[],{"trials":4658,"activeCount":100},[],{"trials":4660,"activeCount":100},[],{"trials":4662,"activeCount":100},[],{"trials":4664,"activeCount":100},[],{"intervention":4666,"totalTrials":96,"cells":4667},"MAL",{"EARLY_PHASE1":4668,"PHASE1":4670,"PHASE2":4672,"PHASE3":4674,"PHASE4":4676,"NA":4678},{"trials":4669,"activeCount":100},[],{"trials":4671,"activeCount":100},[],{"trials":4673,"activeCount":100},[],{"trials":4675,"activeCount":100},[],{"trials":4677,"activeCount":100},[],{"trials":4679,"activeCount":100},[4680],{"nctId":4681,"briefTitle":4682,"status":785,"phases":4683,"primaryCompletion":1704,"completion":1704,"start":4684,"enrollment":2354,"conditions":4685,"interventions":4688},"NCT03012009","Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial",[92],"2014-09",[4686,4687],"Bowen's Disease","Superficial Basal Cell Carcinoma",[4666,4689],"lidocaine hydrochloride 2% with epinephrine",{"intervention":4689,"totalTrials":96,"cells":4691},{"EARLY_PHASE1":4692,"PHASE1":4694,"PHASE2":4696,"PHASE3":4698,"PHASE4":4700,"NA":4702},{"trials":4693,"activeCount":100},[],{"trials":4695,"activeCount":100},[],{"trials":4697,"activeCount":100},[],{"trials":4699,"activeCount":100},[],{"trials":4701,"activeCount":100},[],{"trials":4703,"activeCount":100},[4704],{"nctId":4681,"briefTitle":4682,"status":785,"phases":4705,"primaryCompletion":1704,"completion":1704,"start":4684,"enrollment":2354,"conditions":4706,"interventions":4707},[92],[4686,4687],[4666,4689],{"intervention":4709,"totalTrials":96,"cells":4710},"EmbryoGlue®, Vitrolife",{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4715,"PHASE3":4717,"PHASE4":4719,"NA":4721},{"trials":4712,"activeCount":100},[],{"trials":4714,"activeCount":100},[],{"trials":4716,"activeCount":100},[],{"trials":4718,"activeCount":100},[],{"trials":4720,"activeCount":100},[],{"trials":4722,"activeCount":100},[4723],{"nctId":4724,"briefTitle":4725,"status":1888,"phases":4726,"primaryCompletion":1891,"completion":4727,"start":2910,"enrollment":4728,"conditions":4729,"interventions":4731},"NCT04709796","The Use of High Concentration Hyaluronic Acid (HA) Transfer Medium in Repeated Implantation Failure (RIF) Patients",[92],"2025-06-30",178,[1897,2708,4730],"Miscarriage, Recurrent",[4709,4732],"Conventional Transfer",{"intervention":4732,"totalTrials":96,"cells":4734},{"EARLY_PHASE1":4735,"PHASE1":4737,"PHASE2":4739,"PHASE3":4741,"PHASE4":4743,"NA":4745},{"trials":4736,"activeCount":100},[],{"trials":4738,"activeCount":100},[],{"trials":4740,"activeCount":100},[],{"trials":4742,"activeCount":100},[],{"trials":4744,"activeCount":100},[],{"trials":4746,"activeCount":100},[4747],{"nctId":4724,"briefTitle":4725,"status":1888,"phases":4748,"primaryCompletion":1891,"completion":4727,"start":2910,"enrollment":4728,"conditions":4749,"interventions":4750},[92],[1897,2708,4730],[4709,4732],{"intervention":4752,"totalTrials":96,"cells":4753},"Procedural sedation with ketofol in a 1 on 4 ratio",{"EARLY_PHASE1":4754,"PHASE1":4756,"PHASE2":4758,"PHASE3":4760,"PHASE4":4762,"NA":4764},{"trials":4755,"activeCount":100},[],{"trials":4757,"activeCount":100},[],{"trials":4759,"activeCount":100},[],{"trials":4761,"activeCount":100},[],{"trials":4763,"activeCount":100},[],{"trials":4765,"activeCount":100},[4766],{"nctId":4767,"briefTitle":4768,"status":785,"phases":4769,"primaryCompletion":4770,"completion":4770,"start":4771,"enrollment":4772,"conditions":4773,"interventions":4775},"NCT04028141","Evaluation of a New Protocol for Adult Procedural Sedation With Ketamine-propofol in a 1 on 4 Ratio",[],"2019-03-31","2018-02-01",61,[4774],"Procedural Sedation and Analgesia",[4752],{"intervention":4777,"totalTrials":96,"cells":4778},"Dermatix",{"EARLY_PHASE1":4779,"PHASE1":4781,"PHASE2":4783,"PHASE3":4785,"PHASE4":4787,"NA":4789},{"trials":4780,"activeCount":100},[],{"trials":4782,"activeCount":100},[],{"trials":4784,"activeCount":100},[],{"trials":4786,"activeCount":100},[],{"trials":4788,"activeCount":100},[],{"trials":4790,"activeCount":100},[4791],{"nctId":4792,"briefTitle":4793,"status":785,"phases":4794,"primaryCompletion":4795,"completion":4795,"start":4796,"enrollment":4797,"conditions":4798,"interventions":4800},"NCT01413789","Measurement and Comparison of the Occlusive and Hydrating Capacity of Three Silicone Gels and One Gel Cream",[92],"2012-07","2011-06",55,[4799],"Scar Tissue or Healthy Skin",[4777,4801,4802,4803,4804,4805,4806,4807],"Kelocote","BAP scar gel","Alhydran","Bap Scar Care T","Bap Scar Care S","Mepiform","Scar Ban Elastic",{"intervention":4801,"totalTrials":96,"cells":4809},{"EARLY_PHASE1":4810,"PHASE1":4812,"PHASE2":4814,"PHASE3":4816,"PHASE4":4818,"NA":4820},{"trials":4811,"activeCount":100},[],{"trials":4813,"activeCount":100},[],{"trials":4815,"activeCount":100},[],{"trials":4817,"activeCount":100},[],{"trials":4819,"activeCount":100},[],{"trials":4821,"activeCount":100},[4822],{"nctId":4792,"briefTitle":4793,"status":785,"phases":4823,"primaryCompletion":4795,"completion":4795,"start":4796,"enrollment":4797,"conditions":4824,"interventions":4825},[92],[4799],[4777,4801,4802,4803,4804,4805,4806,4807],{"intervention":4802,"totalTrials":96,"cells":4827},{"EARLY_PHASE1":4828,"PHASE1":4830,"PHASE2":4832,"PHASE3":4834,"PHASE4":4836,"NA":4838},{"trials":4829,"activeCount":100},[],{"trials":4831,"activeCount":100},[],{"trials":4833,"activeCount":100},[],{"trials":4835,"activeCount":100},[],{"trials":4837,"activeCount":100},[],{"trials":4839,"activeCount":100},[4840],{"nctId":4792,"briefTitle":4793,"status":785,"phases":4841,"primaryCompletion":4795,"completion":4795,"start":4796,"enrollment":4797,"conditions":4842,"interventions":4843},[92],[4799],[4777,4801,4802,4803,4804,4805,4806,4807],{"intervention":4803,"totalTrials":96,"cells":4845},{"EARLY_PHASE1":4846,"PHASE1":4848,"PHASE2":4850,"PHASE3":4852,"PHASE4":4854,"NA":4856},{"trials":4847,"activeCount":100},[],{"trials":4849,"activeCount":100},[],{"trials":4851,"activeCount":100},[],{"trials":4853,"activeCount":100},[],{"trials":4855,"activeCount":100},[],{"trials":4857,"activeCount":100},[4858],{"nctId":4792,"briefTitle":4793,"status":785,"phases":4859,"primaryCompletion":4795,"completion":4795,"start":4796,"enrollment":4797,"conditions":4860,"interventions":4861},[92],[4799],[4777,4801,4802,4803,4804,4805,4806,4807],{"intervention":4804,"totalTrials":96,"cells":4863},{"EARLY_PHASE1":4864,"PHASE1":4866,"PHASE2":4868,"PHASE3":4870,"PHASE4":4872,"NA":4874},{"trials":4865,"activeCount":100},[],{"trials":4867,"activeCount":100},[],{"trials":4869,"activeCount":100},[],{"trials":4871,"activeCount":100},[],{"trials":4873,"activeCount":100},[],{"trials":4875,"activeCount":100},[4876],{"nctId":4792,"briefTitle":4793,"status":785,"phases":4877,"primaryCompletion":4795,"completion":4795,"start":4796,"enrollment":4797,"conditions":4878,"interventions":4879},[92],[4799],[4777,4801,4802,4803,4804,4805,4806,4807],{"intervention":4805,"totalTrials":96,"cells":4881},{"EARLY_PHASE1":4882,"PHASE1":4884,"PHASE2":4886,"PHASE3":4888,"PHASE4":4890,"NA":4892},{"trials":4883,"activeCount":100},[],{"trials":4885,"activeCount":100},[],{"trials":4887,"activeCount":100},[],{"trials":4889,"activeCount":100},[],{"trials":4891,"activeCount":100},[],{"trials":4893,"activeCount":100},[4894],{"nctId":4792,"briefTitle":4793,"status":785,"phases":4895,"primaryCompletion":4795,"completion":4795,"start":4796,"enrollment":4797,"conditions":4896,"interventions":4897},[92],[4799],[4777,4801,4802,4803,4804,4805,4806,4807],{"intervention":4806,"totalTrials":96,"cells":4899},{"EARLY_PHASE1":4900,"PHASE1":4902,"PHASE2":4904,"PHASE3":4906,"PHASE4":4908,"NA":4910},{"trials":4901,"activeCount":100},[],{"trials":4903,"activeCount":100},[],{"trials":4905,"activeCount":100},[],{"trials":4907,"activeCount":100},[],{"trials":4909,"activeCount":100},[],{"trials":4911,"activeCount":100},[4912],{"nctId":4792,"briefTitle":4793,"status":785,"phases":4913,"primaryCompletion":4795,"completion":4795,"start":4796,"enrollment":4797,"conditions":4914,"interventions":4915},[92],[4799],[4777,4801,4802,4803,4804,4805,4806,4807],{"intervention":4807,"totalTrials":96,"cells":4917},{"EARLY_PHASE1":4918,"PHASE1":4920,"PHASE2":4922,"PHASE3":4924,"PHASE4":4926,"NA":4928},{"trials":4919,"activeCount":100},[],{"trials":4921,"activeCount":100},[],{"trials":4923,"activeCount":100},[],{"trials":4925,"activeCount":100},[],{"trials":4927,"activeCount":100},[],{"trials":4929,"activeCount":100},[4930],{"nctId":4792,"briefTitle":4793,"status":785,"phases":4931,"primaryCompletion":4795,"completion":4795,"start":4796,"enrollment":4797,"conditions":4932,"interventions":4933},[92],[4799],[4777,4801,4802,4803,4804,4805,4806,4807],{"intervention":4935,"totalTrials":96,"cells":4936},"Anticholinergic therapy",{"EARLY_PHASE1":4937,"PHASE1":4939,"PHASE2":4941,"PHASE3":4943,"PHASE4":4945,"NA":4947},{"trials":4938,"activeCount":100},[],{"trials":4940,"activeCount":100},[],{"trials":4942,"activeCount":100},[],{"trials":4944,"activeCount":100},[],{"trials":4946,"activeCount":100},[],{"trials":4948,"activeCount":100},[4949],{"nctId":4950,"briefTitle":4951,"status":785,"phases":4952,"start":4953,"enrollment":4954,"conditions":4955,"interventions":4957},"NCT00148005","Prevalence, Etiology and Therapy of Micturition Disorders of Children With a Mental and\u002For Motoric Disability",[92],"2004-09",250,[4956],"Micturition Disorder",[4935],{"intervention":4959,"totalTrials":96,"cells":4960},"Application of Aruba Aloë formula F-BC-096 or control",{"EARLY_PHASE1":4961,"PHASE1":4963,"PHASE2":4965,"PHASE3":4967,"PHASE4":4969,"NA":4971},{"trials":4962,"activeCount":100},[],{"trials":4964,"activeCount":100},[],{"trials":4966,"activeCount":100},[],{"trials":4968,"activeCount":100},[],{"trials":4970,"activeCount":100},[],{"trials":4972,"activeCount":100},[4973],{"nctId":4974,"briefTitle":4975,"status":1044,"phases":4976,"enrollment":100,"conditions":4977,"interventions":4979},"NCT00389753","Aruba Aloë Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure",[92],[4978],"Hydration of Scars",[4959],{"intervention":4981,"totalTrials":96,"cells":4982},"Adalimumab and Infliximab",{"EARLY_PHASE1":4983,"PHASE1":4985,"PHASE2":4987,"PHASE3":4989,"PHASE4":4991,"NA":4993},{"trials":4984,"activeCount":100},[],{"trials":4986,"activeCount":100},[],{"trials":4988,"activeCount":100},[],{"trials":4990,"activeCount":100},[],{"trials":4992,"activeCount":100},[],{"trials":4994,"activeCount":100},[4995],{"nctId":4996,"briefTitle":4997,"status":785,"phases":4998,"primaryCompletion":4999,"completion":4999,"start":995,"enrollment":5000,"conditions":5001,"interventions":5003},"NCT01338740","Switching From Adalimumab to Infliximab",[],"2014-02-17",21,[5002],"Crohn's Disease",[4981],{"intervention":5005,"totalTrials":96,"cells":5006},"SSRI",{"EARLY_PHASE1":5007,"PHASE1":5009,"PHASE2":5011,"PHASE3":5013,"PHASE4":5015,"NA":5017},{"trials":5008,"activeCount":100},[],{"trials":5010,"activeCount":100},[],{"trials":5012,"activeCount":100},[],{"trials":5014,"activeCount":100},[],{"trials":5016,"activeCount":100},[],{"trials":5018,"activeCount":100},[5019],{"nctId":5020,"briefTitle":5021,"status":785,"phases":5022,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":5025,"conditions":5026,"interventions":5029},"NCT03288675","Stepped Care AiTBS 2 Depression Study (Ghent)",[92],"2023-12-31","2017-10-05",68,[5027,570,5028],"Depressive Disorder, Major","Melancholia",[5005],{"intervention":5031,"totalTrials":96,"cells":5032},"MP29-02",{"EARLY_PHASE1":5033,"PHASE1":5035,"PHASE2":5037,"PHASE3":5039,"PHASE4":5041,"NA":5043},{"trials":5034,"activeCount":100},[],{"trials":5036,"activeCount":100},[],{"trials":5038,"activeCount":100},[],{"trials":5040,"activeCount":100},[],{"trials":5042,"activeCount":100},[],{"trials":5044,"activeCount":100},[5045],{"nctId":5046,"briefTitle":5047,"status":1044,"phases":5048,"primaryCompletion":3186,"completion":3186,"start":2214,"enrollment":100,"conditions":5049,"interventions":5051},"NCT02883439","Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate",[92],[5050],"Bioavailability Study",[5031,5052],"Fluticasone propionate",{"intervention":5052,"totalTrials":96,"cells":5054},{"EARLY_PHASE1":5055,"PHASE1":5057,"PHASE2":5059,"PHASE3":5061,"PHASE4":5063,"NA":5065},{"trials":5056,"activeCount":100},[],{"trials":5058,"activeCount":100},[],{"trials":5060,"activeCount":100},[],{"trials":5062,"activeCount":100},[],{"trials":5064,"activeCount":100},[],{"trials":5066,"activeCount":100},[5067],{"nctId":5046,"briefTitle":5047,"status":1044,"phases":5068,"primaryCompletion":3186,"completion":3186,"start":2214,"enrollment":100,"conditions":5069,"interventions":5070},[92],[5050],[5031,5052],{"intervention":5072,"totalTrials":96,"cells":5073},"Enoxaparin",{"EARLY_PHASE1":5074,"PHASE1":5076,"PHASE2":5078,"PHASE3":5080,"PHASE4":5082,"NA":5084},{"trials":5075,"activeCount":100},[],{"trials":5077,"activeCount":100},[],{"trials":5079,"activeCount":100},[],{"trials":5081,"activeCount":100},[],{"trials":5083,"activeCount":100},[],{"trials":5085,"activeCount":100},[5086],{"nctId":5087,"briefTitle":5088,"status":785,"phases":5089,"primaryCompletion":1824,"completion":5090,"start":5091,"enrollment":5092,"conditions":5093,"interventions":5097},"NCT05224388","Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.",[],"2022-09-15","2020-01-01",813,[1403,5094,5095,5096],"Deep Vein Thrombosis","Anticoagulants and Bleeding Disorders","Critical Illness",[5072,5098],"Heparin",{"intervention":5098,"totalTrials":96,"cells":5100},{"EARLY_PHASE1":5101,"PHASE1":5103,"PHASE2":5105,"PHASE3":5107,"PHASE4":5109,"NA":5111},{"trials":5102,"activeCount":100},[],{"trials":5104,"activeCount":100},[],{"trials":5106,"activeCount":100},[],{"trials":5108,"activeCount":100},[],{"trials":5110,"activeCount":100},[],{"trials":5112,"activeCount":100},[5113],{"nctId":5087,"briefTitle":5088,"status":785,"phases":5114,"primaryCompletion":1824,"completion":5090,"start":5091,"enrollment":5092,"conditions":5115,"interventions":5116},[],[1403,5094,5095,5096],[5072,5098],{"intervention":5118,"totalTrials":96,"cells":5119},"Preservative-free artificial tears",{"EARLY_PHASE1":5120,"PHASE1":5122,"PHASE2":5124,"PHASE3":5126,"PHASE4":5128,"NA":5130},{"trials":5121,"activeCount":100},[],{"trials":5123,"activeCount":100},[],{"trials":5125,"activeCount":100},[],{"trials":5127,"activeCount":100},[],{"trials":5129,"activeCount":100},[],{"trials":5131,"activeCount":100},[5132],{"nctId":5133,"briefTitle":5134,"status":785,"phases":5135,"primaryCompletion":5136,"completion":49,"start":5137,"enrollment":5138,"conditions":5139,"interventions":5141},"NCT07469865","Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST)",[92],"2024-11-14","2021-11-30",46,[5140],"Dry Eye Disease",[5118,5142,5143],"Autologous serum eyedrops 20%","Autologous serum eyedrops 100%",{"intervention":5142,"totalTrials":96,"cells":5145},{"EARLY_PHASE1":5146,"PHASE1":5148,"PHASE2":5150,"PHASE3":5152,"PHASE4":5154,"NA":5156},{"trials":5147,"activeCount":100},[],{"trials":5149,"activeCount":100},[],{"trials":5151,"activeCount":100},[],{"trials":5153,"activeCount":100},[],{"trials":5155,"activeCount":100},[],{"trials":5157,"activeCount":100},[5158],{"nctId":5133,"briefTitle":5134,"status":785,"phases":5159,"primaryCompletion":5136,"completion":49,"start":5137,"enrollment":5138,"conditions":5160,"interventions":5161},[92],[5140],[5118,5142,5143],{"intervention":5143,"totalTrials":96,"cells":5163},{"EARLY_PHASE1":5164,"PHASE1":5166,"PHASE2":5168,"PHASE3":5170,"PHASE4":5172,"NA":5174},{"trials":5165,"activeCount":100},[],{"trials":5167,"activeCount":100},[],{"trials":5169,"activeCount":100},[],{"trials":5171,"activeCount":100},[],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[5176],{"nctId":5133,"briefTitle":5134,"status":785,"phases":5177,"primaryCompletion":5136,"completion":49,"start":5137,"enrollment":5138,"conditions":5178,"interventions":5179},[92],[5140],[5118,5142,5143],{"intervention":5181,"totalTrials":96,"cells":5182},"Nuvaring",{"EARLY_PHASE1":5183,"PHASE1":5185,"PHASE2":5187,"PHASE3":5189,"PHASE4":5191,"NA":5193},{"trials":5184,"activeCount":100},[],{"trials":5186,"activeCount":100},[],{"trials":5188,"activeCount":100},[],{"trials":5190,"activeCount":100},[],{"trials":5192,"activeCount":100},[],{"trials":5194,"activeCount":100},[5195],{"nctId":5196,"briefTitle":5197,"status":785,"phases":5198,"primaryCompletion":5199,"completion":3053,"start":3006,"enrollment":401,"conditions":5200,"interventions":5201},"NCT00374387","Psychosocial and Physiological Mechanisms in the Effect of Hormonal Contraception on the Female Sexual Desire",[92],"2009-08",[34],[5181,5202,5203],"low-dose combination pill","minipill",{"intervention":5202,"totalTrials":96,"cells":5205},{"EARLY_PHASE1":5206,"PHASE1":5208,"PHASE2":5210,"PHASE3":5212,"PHASE4":5214,"NA":5216},{"trials":5207,"activeCount":100},[],{"trials":5209,"activeCount":100},[],{"trials":5211,"activeCount":100},[],{"trials":5213,"activeCount":100},[],{"trials":5215,"activeCount":100},[],{"trials":5217,"activeCount":100},[5218],{"nctId":5196,"briefTitle":5197,"status":785,"phases":5219,"primaryCompletion":5199,"completion":3053,"start":3006,"enrollment":401,"conditions":5220,"interventions":5221},[92],[34],[5181,5202,5203],{"intervention":5203,"totalTrials":96,"cells":5223},{"EARLY_PHASE1":5224,"PHASE1":5226,"PHASE2":5228,"PHASE3":5230,"PHASE4":5232,"NA":5234},{"trials":5225,"activeCount":100},[],{"trials":5227,"activeCount":100},[],{"trials":5229,"activeCount":100},[],{"trials":5231,"activeCount":100},[],{"trials":5233,"activeCount":100},[],{"trials":5235,"activeCount":100},[5236],{"nctId":5196,"briefTitle":5197,"status":785,"phases":5237,"primaryCompletion":5199,"completion":3053,"start":3006,"enrollment":401,"conditions":5238,"interventions":5239},[92],[34],[5181,5202,5203],{"intervention":5241,"totalTrials":96,"cells":5242},"Urinary proteomic analysis",{"EARLY_PHASE1":5243,"PHASE1":5245,"PHASE2":5247,"PHASE3":5249,"PHASE4":5251,"NA":5253},{"trials":5244,"activeCount":100},[],{"trials":5246,"activeCount":100},[],{"trials":5248,"activeCount":100},[],{"trials":5250,"activeCount":100},[],{"trials":5252,"activeCount":100},[],{"trials":5254,"activeCount":100},[5255],{"nctId":5256,"briefTitle":5257,"status":785,"phases":5258,"primaryCompletion":5259,"completion":5259,"start":5260,"enrollment":401,"conditions":5261,"interventions":5263},"NCT01981993","Validation of a Urinary Biomarker as Diagnostic Tool for AKI in Sepsis",[],"2011-03-27","2009-06-04",[5262],"Sepsis at Intensive Care Unit",[5241],{"intervention":5265,"totalTrials":96,"cells":5266},"Volulyte 6%",{"EARLY_PHASE1":5267,"PHASE1":5269,"PHASE2":5271,"PHASE3":5273,"PHASE4":5275,"NA":5277},{"trials":5268,"activeCount":100},[],{"trials":5270,"activeCount":100},[],{"trials":5272,"activeCount":100},[],{"trials":5274,"activeCount":100},[],{"trials":5276,"activeCount":100},[],{"trials":5278,"activeCount":100},[5279],{"nctId":5280,"briefTitle":5281,"status":785,"phases":5282,"primaryCompletion":5283,"completion":1706,"start":2775,"enrollment":1245,"conditions":5284,"interventions":5287},"NCT02034682","The Effect of Hydroxyethylstarch 6% 130\u002F0.4 in a Balanced Electrolyte Solution (Volulyte®) Compared to Gelatine (Geloplasma®) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy",[92],"2014-08",[5285,5286],"Microvascular Reactivity","Tissue Oxygen Saturation",[5265,5288],"Geloplasma",{"intervention":5288,"totalTrials":96,"cells":5290},{"EARLY_PHASE1":5291,"PHASE1":5293,"PHASE2":5295,"PHASE3":5297,"PHASE4":5299,"NA":5301},{"trials":5292,"activeCount":100},[],{"trials":5294,"activeCount":100},[],{"trials":5296,"activeCount":100},[],{"trials":5298,"activeCount":100},[],{"trials":5300,"activeCount":100},[],{"trials":5302,"activeCount":100},[5303],{"nctId":5280,"briefTitle":5281,"status":785,"phases":5304,"primaryCompletion":5283,"completion":1706,"start":2775,"enrollment":1245,"conditions":5305,"interventions":5306},[92],[5285,5286],[5265,5288]]